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Introduction: Although the average life expectancy of humans has been increasing 
steadily with advances in medicine, neurodegenerative disease such as Alzheimer 
disease (AD), Parkinson disease (PD), or Amyotrophic lateral sclerosis (ALS) has 
been decreasing the quality of life for humans. At the molecular level, it is essential 
to study the causes and mechanisms of these neurodegenerative diseases. In recent 
years, proteomics using high-resolution mass spectrometry has emerged as a useful 
technique for discovering marker proteins. In addition, a systematic network analysis 
of target proteins could be used to study mechanisms of neurodegenerative disease 
in the future. 
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Methods: In Chapter I, neuronal cell line (HT-22), astrocytic cell line (C8-D1A), 
and microglia cell line (BV-2) were used for the analysis of secretory protein analysis 
in central nervous system. 1x10e6 cells were cultured in a 100-mm dish for 24 hours, 
and the proteins obtained by concentration were treated with peptides using the FASP 
(Filter Aided Sample Preparation) technique and analyzed by Q-Exactive, a high-
resolution mass spectrometer, for 4 hours. Data were processed with the MaxQuant 
program based on the Andromeda algorithm, and un-annotated MS/MS data were 
analyzed with the de-novo sequencing based PEAKS-7 program to identify 
additional proteins. The secretory proteins of each cell line were compared and 
analyzed by label-free quantitation technique, and the important functions of the 
secreted proteins were confirmed using the bioinformatics tool. In Chapter II, 
microglial cell lines were treated with lipopolysaccharide (LPS) and interferon 
gamma (IFN-γ) for 24 h, and proteins expressed in intracellular and extracellular 
were simultaneously quantified using dimethyl labeling analysis. In order to examine 
the changes in the candidate protein groups in the intra- and extracellular microglial 
cells activated with LPS, IFN-γ and LPS / IFN-γ for 6, 12, 24 and 48 hours, I 
conducted a systematic network analysis of the proteomes that change with time by 
performing relative quantification with label-free PRM (Parallel Reaction 
Monitoring). 
 
Results: In Chapter I, 2795 secretory proteins were identified in three cell lines using 
a high-resolution mass spectrometer. In addition, 156 (BV-2), 44 (C8-D1A), and 93 
(HT-22) cell-specific secretory proteins were identified. I also identified 302 
additional proteins using de-novo sequencing analysis techniques. In order to 
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increase the reliability of excised secreted proteins, 2351 putative secretory proteins 
were classified using SignalP, SecretomeP, Exocarta and TMHMM database tools. 
The quantitative comparison analysis method with 2 fold-change between each cell 
secretory protein were confirmed 573 (BV-2 vs. C8-D1A), 694 (BV-2 vs. HT-22), 
and 475 (C8-D1A vs. HT, -22) putative secreted proteins. Pathway analysis of 
quantified proteins revealed important functions of secretory proteins such as 
lysosome and phagocytosis, and proteins associated with neurodegenerative diseases 
such as Parkinson disease and Huntington disease. In Chapter II, I investigated whole 
cell proteome (WCP) analysis of LPS and LPS / IFN-γ activated protein to identify 
5492 proteins and quantify 4748 proteins. Analyze the same model of extracellular 
secretory proteome (SEC), 4938 proteins and 3558 proteins were identified and 
quantified, respectively. A total of 319 intracellular proteins and 170 secreted 
proteins were selected as final target candidates through analysis of bioinformatics 
such as KEGG pathway for statistically significant proteins. Using a label-free PRM 
technique that optimizes simultaneous quantitation of more than 450 peptides, I were 
able to draw a pathway network map that varies with activation time. In addition, I 
could suggest candidate protein markers that show intracellular and extracellular 
differences in activated microglial cell model. 
Conclusions: Secretory protein differences of three cell lines were identified by 
label-free quantification through optimization and development of secretory 
proteome technique. These secretory proteomics techniques provide a basis for in-
depth and accurate research of extracellular proteins that are present in small 
amounts. In addition, I aimed to investigate mechanism of degenerative brain disease 
by identifying marker proteins expressed during activation of microglial cells that 
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are immunocompetent in the CNS through a systematic quantitative proteomics 
approach on a single platform. Simultaneous quantification of dimethyl labeling and 
label-free PRM targeted proteomics were established for more precise and accurate 
quantitative analysis. In addition, quantitative analysis of the proteins involved in 
immune-inflammatory response and metabolism during microglial activation could 
be used to identify marker proteins that specifically expressed LPS and IFN-γ. 
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The central nervous system (CNS) comprises two major cell types, neurons 
and glia 1-2. Neurons have been reflected to be the core components of the CNS, 
whereas glia were simply physical and metabolic support cells. However, recent 
studies 3-4 have showed that glia are significant mediators in the development, 
maintenance, and function of the nervous system and in disorders of the CNS. 
Further, impaired communication between neurons and glia alter normal brain 
function and effect neurodegenerative processes, including Parkinson disease (PD), 
Alzheimer disease (AD), and amyotrophic lateral sclerosis (ALS) 3, 5.  
The recruitment and activation of glia cells, primarily astrocytes and 
microglia in the CNS, require constant shared communication between neurons and 
glia and among glial cells 3, 5. Subsequently, reactive glial cells interpret extracellular 
cues to regulate neuronal function. Astrocyte and microglia communicate primarily 
with each other and neurons through secreted proteins, which mediate and modulate 
many normal and pathological processes in the CNS 5. Thus, an in-depth proteomic 
analysis of secreted proteins is crucial to increase our understanding of the molecular 
interactions between neurons, astrocytes, and microglia under physiological and 
neuropathological conditions 5.  
Mass spectrometry (MS)-based shotgun proteomic methods allow one to 
profile secreted proteins, and significant effort has been directed toward analyzing 
the proteomic profiles 6-9 of secreted proteins from astrocytes, microglia, and neurons. 
However, the integrated profile of the CNS secretome is limited, although research 
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on individual secretomes has made remarkable progress in recent years. Further, 
neuron-, astrocyte-, and microglia-secreted proteins have not been systematically 
identified or quantified largely under non-disease or inactive conditions, demanding 
improvements in the depth of coverage of the secretome. 
 First in Chapter I, I attempted to generate a large scale of secretome from 
microglia (BV-2), astrocyte (C8-D1A), and neuron (HT-22) mouse cell lines by 
combining filter aided sample preparation (FASP) method with high-resolution LC-
MS/MS. The data were analyzed using MaxQuant and PEAKS 7 softwares for 
identification of proteins and quantification of differentially expressed proteins. 
Proteins identified in the conditioned media of three cell lines were processed using 
SignalP and SecretomeP softwares to predict the existence of signal peptide cleavage 
sites and to determine if a protein is non-classically secreted, respectively. This study 
contributed to the development of methods for analyzing proteins secreted from cell 
lines by proteomics using mass spectrometry. The technique of in-depth secretome 
analysis could be used to perform the following studies. 
In Chapter 2, I focused on microglia to better understand the neuroimmune 
system. Microglia are cellular sentinels of innate immunity that are critical in the 
development of neurodegenerative diseases, the prevalence of which has risen 
worldwide as the average life expectancy has increased steadily. According to a 
recent study, microglia help maintain immune surveillance by responding quickly to 
pathogens that enter the parenchyma when the central nervous system (CNS) is 
compromised by foreign invaders 10. Microglia have many functions, including 
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antigen presentation and processing 11, activation of T cells and B cells 12, and 
initiation of nonspecific immune responses following stimulation.  
Microglia undergo a series of morphological changes in their active state. 
As part of this process, various surface receptors are upregulated to create a variety 
of biochemical repertoires that help in different subtypes of the immune reaction 13. 
Moreover, microglial activation-mediated inflammatory responses normally cause 
neuronal damage and remove damaged cells through phagocytosis 14-15. Activated 
microglia express various cytokines and growth factors in response to nerve injuries 
under pathological conditions 16. To observe the active states of intracellular and 
intercellular microglia, two major inflammation-associated molecules 
lipopolysaccharide (LPS) and interferon-gamma (IFN-γ) have been used to stimulate 
BV2 mouse microglial cells. LPS induces dopaminergic neurodegeneration through 
NF-kB and Toll-like receptor signaling 17-18. IFN-γ activates microbicidal effector 
functions through JAK-STAT signaling and the enhancement of innate immune 
responses 19. LPS and IFN-γ synergize to amplify the expression of nitric oxide 
synthase (iNOS), which increases nitric oxide (NO) production 20-21. The microglial 
active state has been examined simply with regard to a few factors to several hundred 
associated molecules 22-25 and has not been analyzed on a proteomic scale that takes 
into account the related pathway networks. 
I have also attempted a systematic approach to combine global proteomics 
with targeted proteomics to further improve the technology. Many studies have 
attempted to identify specific proteins using a quantitative proteomics approach 26-28. 
However, conventional targeted methods, such selected reaction monitoring (SRM)-
based targeted proteomics, are labor-intensive and inconvenient, because separate 
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platforms are used for the discovery and targeted analysis 29. Moreover, one is 
restricted to analyzing 100–200 target peptides, rendering this approach unsuitable 
for larger-scale applications 30. To overcome these limitations, I designed a 
systematic proteomics approach that can track changes in more proteins on a single 
platform by mass spectrometry compared with current methods. 
On a high-resolution quadrupole orbitrap, parallel reaction monitoring 
(PRM) can acquire full MS/MS spectra with high specificity and separate co-isolated 
interference ions from target peptides with a tolerance of approximately 10–20 ppm 
31. Technically, PRM can be performed with or without labels. A label-based method 
can be used to determine the absolute and relative levels of proteins in samples by 
spiking them with heavy isotope-labeled synthetic peptides, analogous to targeted 
endogenous peptides. In contrast, the label-free method is straightforward and 
suitable for hyper-multiplexed targeted proteomics for semi-quantitative 
measurements 32. For label-free PRM approaches, single or multiple heavy isotope-
labeled reference peptides (LRPs) can help normalize the peak areas of all 
endogenous target peptides, assess the performance of the system, and correct for 
variations in retention time shifts between LC runs 33-34.  
In this study, dimethyl-labeled proteomics and label-free PRM were used 
to develop a systematic proteomics approach that allows simultaneous and targeted 
quantification on a high-resolution Q-Exactive orbitrap MS platform. Using this 
method, I examined the dynamic changes in proteins during microglial activation, 
induced by a single effector or a combination of factors. Our approach enabled the 
quantification of over 450 peptides in a single run by label- targeted analysis. Thus, 
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systematic proteomics identifies intracellular and intercellular proteins, the 
expression of which is regulated significantly during activation. 
 Based on these data, the construction and analysis of a pathway network 
model of proteins can reveal latent pathways that are associated with 
neurodegenerative diseases. Furthermore, this systematical quantification platform 





Subtitle: In-depth characterization of the secretome of mouse 
CNS cell lines with LC-MS/MS 
 
METERIALS AND METHODS 
Cell culture and conditioned media collection 
The 3 cell lines were cultured in 100-mm dishes with DMEM, 
supplemented with 10% inactivated FBS and 100 U/mL of penicillin-streptomycin, 
at 37°C with 5% CO2. Then, the putatively secreted proteins were purified from the 
conditioned media (CM). Briefly, 1 x 106 cells were washed with PBS and incubated 
in serum- and phenol red-free media for 24 h. The CM was collected and centrifuged 
at 3000 rpm for 3 min to remove intact cells. After being passed through a 0.22-m 
membrane, the CM was concentrated on an Amicon Ultra-centrifugal filter (EMD 
Millipore, Billerica, MA, USA). Protein concentration was measured using a BCA 
reducing agent compatibility assay kit (Thermo Scientific, Rockford, IL, USA). All 
procedures were performed in biological triplicates for each cell line. 
 
Protein digestion and desalting 
Proteins were digested by FASP as described with some modifications 6, 35. 
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Briefly, proteins (200 g) were mixed with SDT buffer (4% SDS and 0.1 M DTT in 
0.1 M Tris-HCl, pH 7.4) and loaded onto a 30 K spin filter (EMD Millipore, Billerica, 
MA, USA). Buffer was exchanged with UA solution (8 M urea in 0.1 M, pH 8.5) by 
centrifugation. Reduced cysteines were alkylated with IAA solution (0.05 M 
iodoacetamide in UA solution) for 30 min at room temperature (RT) in the dark. 
Additional buffer was exchanged with 40 mM ammonium bicarbonate. Protein 
digestion was performed at 37°C overnight with trypsin [enzyme-to-substrate ratio 
(w/w) of 1:100]. The resulting peptides were acidified with 1% TFA and desalted 
using homemade C18 Stage-Tips as described 6, 35. Desalted samples were 
lyophilized in a speed-vacuum centrifuge and stored at -80°C. 
 
Mass spectrometry analysis 
The peptides were analyzed by LC-MS/MS on a Nanoflow Easy-nLC 1000 
(Proxeon Biosystems, Odense, Denmark), coupled to a Q-Exactive mass 
spectrometer (Thermo Scientific, Bremen, Germany) through a nano-electrospray 
ion source, as described with some modifications 35. Desalted peptides (1 g) were 
separated on a 2-column system with a trap column (100 Å , 3-m particle, 75 m x 
2 cm) and an analytical column (100 Å , 1.8-m particle, 50 m x 15 cm) with 180-
min gradients from 5% to 30% acetonitrile and analyzed on the mass spectrometer. 
The samples were analyzed in data-dependent acquisition mode to acquire the mass 
spectra, and the MS1 spectra were measured at a resolution of 70,000 and an AGC 
target of 3e6. I selected the 20 most abundant ions with an isolation window of 2 m/z. 
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The selected ions were fragmented by HCD with a normalized collision energy of 
27. The maximum ion injection time for the analysis scan and MS/MS scan were 20 
ms and 60 ms, respectively. Each sample was analyzed in triplicate for technical 
replications. 
 
Database search using MaxQuant 
Raw files were processed in MaxQuant (version 1.3.0.5) 36 and using the Andromeda 
search engine 37, based on the IPI mouse database (version 3.87 and 59,534 entries), 
including forward and reverse proteins sequences and common contaminants. 
MS/MS searches were performed with the following parameters: a 6-ppm main 
search tolerance, a 20-ppm first search tolerance, carbamidomethylation as a fixed 
modification, and oxidation of methionine and protein N-terminal acetylation as 
variable modifications. The false discovery rate (FDR) for all peptides and protein 
identifications was set to 0.01. Label-free quantitation (LFQ) was performed in 
MaxQuant as described 38. Briefly, the normalized spectral protein intensity (LFQ 
intensity) from MaxQuant was used as the protein intensity. Quantitation schemes 





Figure 1-1. Detailed flowchart of the proteomic approach, label-free 




Database search using PEAKS 7 
 To rescue unassigned MS/MS spectra resulted from MaxQuant search, I 
used the PEAKS 7 program that search MS/MS peaks by de novo sequencing, which 
generates amino acid sequences from the tandem mass spectrum of peptides without 
a database. After I extracted unassigned MS/MS spectra using MSconvert, spectrum 
files that were converted to mzXML were re-analyzed using PEAKS 7. The standard 
workflow PEAKS, comprising de novo sequencing, PEAKS DB, PEAKS PTM, and 
SPIDER, was performed to analyze data with high sensitivity and accuracy 39. 
 First, in the de novo step, the PEAKS algorithm 39 was used to perform de 
novo sequencing for 604,364 MS/MS spectra. To filter the de novo sequencing 
results, the threshold of average local confidence (ALC) score was set to 50%. I then 
performed a de novo sequencing-assisted database search with PEAKS DB against 
the IPI mouse database (ver. 3.87, 59,534 entries). The search parameters were as 
follows: trypsin as the enzyme, allowing semi-tryptic cleavage; 3 missed cleavages; 
precursor mass error tolerance of 15 ppm; fragment mass error tolerance of 0.02 Da; 
carbamidomethylation (C) as a fixed modification; oxidation (M), pyro-glu (Q and 
E), phosphorylation (S, T and Y), deamidation (N and Q), and acetylation of the 
peptide’s N-terminus as variable modifications. The search results were filtered by a 
threshold score at a 0% FDR at the level of peptide-spectrum match (PSM), peptide, 
and protein to obtain only precise and confident data 40 (corresponding to a peptide 
score of -10logP ≥ 30.7 and protein score of -10logP ≥ 20). 
An additional search for unexpected modifications was performed using the 
PEAKS PTM algorithm against the Unimod database 39. Finally, a homology search, 
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based on de novo sequencing tags, was performed using the SPIDER algorithm to 
identify peptides that resulted from nonspecific cleavages or amino acid substitutions.  
 
Label-free quantitation (pairwise analysis) 
 For relative quantitation in pairwise manner, I applied the label-free 
quantitation (LFQ) approach by comparing the normalized intensities of pairwise 
proteins. The identified proteins from 3 samples were paired to 3 groups (BV-2 vs. 
C8-D1A, C8-D1A vs. HT-22, and BV-2 vs. HT-22). The normalized intensity of each 
protein was calculated using MaxQuant (ver. 1.3.0.5), and the intensities were log-
transformed (log2) in Perseus (ver. 1.4.0.20).  
A total of 9 comparison sets (3 biological replicates per cell line) were 
analyzed using LFQ. First, I required a minimum of 3 valid values in one comparison 
set, which comprised 6 technical replicates (50% detection). Missing values were 
replaced with expected values in Perseus using a normal distribution (width = 0.3; 
shift = 1.8) of the intensity of the proteins. To determine the quantified proteins, 
paired t-test was used with a Benjamini-Hochberg FDR value of 5%. Differentially 
expressed proteins (DEPs) with 2-fold intensity changes in at least 2 of 3 biological 
replicates were assumed to be part of the secretome by the prediction tools. Finally, 
the DEPs annotated as part of the secretome were ultimately considered differentially 
expressed secretion proteins (DESPs). 
Statistical analysis 
Statistical analysis was performed using Perseus as described 38. After log2 
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transformation of the protein intensities, paired t-test was applied to examine the 
differences in protein intensities between samples. The significance of outliers was 
calculated by multiple hypothesis testing (Benjamini Hochberg correction), with a 
threshold value of 0.05.  
 In comparing pairwise samples for label-free quantitation, I processed the 
3 cell lines in cluster with ANOVA. Normalized LFQ intensities of the 3-cell-line 
secretome were categorized into 3 groups and filtered rows, based on proteins that 
had more than 5 valid values out of total 9 replicates (3 technical and 3 biological 
replicates). Following the replacement of missing values from the normal 
distribution parameterized with 0.3 width and 1.8 down shifts, the proteins were 
differentiated by ANOVA at a Benjamini-Hochberg FDR of less than 0.05. After 
normalization of the intensities value with z-score, hierarchical clustering was 
performed using Euclidean distance, complete linkage, and 1000 clusters as 
parameters in Perseus.  
 Principal component analysis (PCA) was performed to confirm the 
statistically correlated variables between cell lines. All lists of proteins and LFQ 
intensities were imported into Perseus, and the proteins categorized to pairwise 
groups. Proteins that contained at least 3 valid values of normalized intensities were 
filtered, and missing values were replaced with putative values from the normal 
distribution. Finally, a PCA graph was drawn in Perseus with non-category 




 To confirm the putative secreted proteins, a bioinformatics analysis was 
performed with SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/), SecretomeP 
2.0 (http://www.cbs.dtu.dk/services/ SecretomeP/), and TMHMM server 2.0 
(http://www.cbs.dtu.dk/services/TMHMM/) and by comparison with the Exocarta 
database (http://www.exocarta.org). The FASTA form of identified proteins was 
exported and used for this analysis. These protein lists were submitted to the SignalP 
4.1 server. The prediction parameters were set up as follows: eukaryotes as the 
organism group and a cutoff value of more than 0.45. To determine whether the 
proteins were non-classically secreted, the SecretomeP 2.0 server was used, with 
mammal as organism and a threshold score of 0.5 as parameters. For the prediction 
of transmembrane helices in the proteins, TMHMM server 2.0 was used with the 




The gene ontology of analyzed proteins was explicated using the DAVID 
bioinformatics tool (http://david.abcc.ncifcrif.gov/) and UniprotKB database 
(http://www.uniprot.org/). Pathways were analyzed using the KEGG and Panther 
databases 41.  
 
Western blot analysis 
To confirm the contamination of CM, whole-cell lysates were prepared by 
lysis in RIPA buffer (8 M urea, 1 mM EDTA, 1% NP-40, Tris-Cl pH 7.4, and 150 
mM NaCl), supplemented with a protease inhibitor cocktail (PMSF). The 
concentration of the whole-cell lysates and CM was determined by BCA assay. Equal 
amounts of proteins (30 μg) in the whole-cell lysates and CM were separated by 12% 
SDS-PAGE and transferred to PVDF (polyvinylidene fluoride) membranes 
(Hybond-P, GE Healthcare). After blocking the membranes with 5% BSA solution 
for 2 hours, they were incubated with the primary β-actin antibodies (1:1000 dilution, 
Sigma Aldrich, Louis, MO, USA) overnight at 4°C.  
To validate results of label-free quantitation analysis, four proteins were 
analyzed in CMs of the 3 cell lines by western blot as described below. The primary 
antibodies were against peroxiredoxin (Prdx2, 1:1000, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), carboxypeptidase E (Cpe, 1:1000, Santa Cruz Biotechnology, 
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Santa Cruz, CA, USA), β-catenin (Ctnnb1, 1:1000, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), and β-filamin (Flnb, 1:1000, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). 
The membranes were washed 5 times with TBS-T (Tris-buffered saline and 
Tween 20) for 1 hr and incubated with horseradish peroxidase-conjugated secondary 
antibodies for 2 hr at room temperature (goat anti-mouse IgG-HRP) (1:5000 dilution 
for each antibody, Santa Cruz Biotechnology, Santa Cruz, CA, USA). After being 
washed with TBS-T for 1 hr, the membranes were developed with a mixture of 
detection solution (West-Q Chemiluminescent Substrate Kit-plus, GenDEPOT, 
Barker, TX, USA) and quantified on an image reader (LAS-4000, Fujifilm, Japan). 






Confirmation of conditioned media samples 
To evaluate interference by intracellular proteins within the secretome of 
the 3 cell lines, I compared the distribution of β-actin between total cell lysates and 
CMs. β-actin signal was only detected in the lysates, confirming high quality of 
secreted proteins (Figure 1-2A). To assess reproducibility of our secretome, 3 
biological replicates of collected CMs were examined by high-resolution mass-
spectrometry with technical triplicates. 
 
Putative secreted proteome 
After a total of 1,950,047 MS/MS scans were accumulated, 29,724 unique 
peptides that matched with 2795 protein groups were identified at an FDR of less 
than 1% by MaxQuant analysis (Figure 1-2B). Of these protein groups, 1975 (71%) 
were common to all 3 cell lines. Total identified proteins were subjected to sequential 
analysis with SignalP, SecretomeP, Exocarta, and TMHMM. Of 2795 proteins, 2125 
proteins (76%) were predicted to be secretion or shedding proteins by the classical 
secretion pathway or a non-classical mechanism in all 3 cell lines (Figure 1-2B, and 
Figure 1-3 and 1-4). This subset of proteins was considered to be the putative 




Rescue of non-annotated MS/MS data 
I searched for non-annotated peptide spectra derived from MaxQuant result 
using PEAKS 7.0, based on a de novo sequencing-assisted database search. From 
604,364 unassigned MS/MS spectra, 95,145 peptide-spectrum matches (PSMs) that 
corresponded to 20,756 peptides and 1804 protein groups were identified at an FDR 
of 0% at the PSM, peptide, and protein levels, whereas 89,095 PSMs comprised 130 
types of post-translational modification. Notably, I newly identified 302 proteins that 
were undetected at first search with MaxQuant, 231 of which were determined to be 





Figure 1-2. Proteomic analysis of secreted proteins from three murine CNS cell 
lines in conditioned media.  
(A) Workflow of proteomic experiments. Illustration below CM collection is 
immune blot validation, describing that the CM does not contain contaminating 
intracellular proteins. (B) Venn diagram of all identified proteins in the 3 cell lines. 
The numbers in parentheses show the predicted secreted proteins. (C) Venn diagram 
of identified proteins from MaxQuant or PEAKS-7. To compare the two sets, the 
protein accession number was converted to the gene symbol. A total of 302 protein 




Figure 1-3. Distribution of putative secreted proteins predicted by 
bioinformatics tools 
Identified proteins from each biological and technical replicate were subjected to 
bioinformatics analysis using the prediction tools SignalP, SecretomeP, Exocarta, 
and TMHMM. The number in each box indicates the resulting amount of putative 





 Figure 1-4. Proportion of putative secreted proteins 
Number of identified proteins and putative secreted proteins are shown in the graph. 
The red dots indicate the percentage of predicted secretion proteins versus identified 
proteins in each cell line. 
 
Characterization of secretome data 
In this study, 87.69% of protein groups were classified by a minimum of 2 
unique peptides. Most proteins were identified with at least 25% sequence coverage 
(Figure 1-5A). In addition, 60% of our 3-cell line secretome was identified with at 
least 5 distinct peptides (Figure 1-5B). The average Andromeda score of the peptides 
was 99.66 (Figure 1-5C). Moreover, the absolute mass deviation ranged from 0.65 
ppm to 0.69 ppm for the analyzed peptides in the replicates. All identified proteins 




Figure 1-5. Characterization of proteomic data 
(A) Sequence coverage of the identified proteins in the total proteome of the 3 cell 
lines. (B) Relative proportions of the number of unique peptides used for 
identification. (C) Histogram of distribution of Andromeda scores of identified 




The technical and biological variations were measured by cross-correlation 
analysis with protein intensities for the replications. I outlined the correlation of the 
intensities for all of replicates (Figure 1-6). The R2 value of the technical replicates 
varied from 0.84 to 0.98. In addition, the average R2 values of the biological 
replicates were 0.94, 0.86, and 0.92 in BV2, C8-D1A, and HT-22, respectively. 
 
Figure 1-6. Reproducibility between proteomics analysis 
Scatterplot of reproducibility between biological and technological triplicates, based 
on the coefficient of determination (R2) in BV-2 (A), C8-D1A (B), and HT-22 (C) 




After log2 tranformation, the median coefficient of variation (CV) values 
for the abundance of proteins in the BV2 cell line were 0.49%, 0.43%, and 0.41% 
within technical replicates and 1.05% between biological replications. In addition, 
the median CVs for the C8D1A cell line were 0.56%, 0.57%, and 0.51% within 
technical replications and 1.49% across biological replicates. The median CVs for 
the HT22 cell line were 0.48%, 0.42%, and 0.45% within technical replicates and 
1.04% between biological replicates (Figure 1-7). By the results, I determined that 
the technical or biological variability was low, demonstrating that our experimental 







Figure 1-7. Precision of proteomic approaches 
Intensity values of label-free quantitation by MaxQuant were transformed to base-2 
logarithms, and the coefficient of variation (CV) values in the technical (A, C) and 
biological replicates (B, D) in the 3 cell lines were calculated, as shown in the box 
plots and histogram, respectively.  
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Label-free quantification of secretome for three cell lines 
To define the CNS cell line-specific secretome, I performed label-free 
quantitation (LFQ) and a bioinformatics analysis using several data improvement 
tools 42. First, I performed principal component analysis (PCA) to compare the 
proteomes of the CNS cell lines. The distance between the technical and biological 
replicates was much smaller than that between cell types, demonstrating that the 
secretome signatures of the 3 cell lines led to robust segregation (Figure 1-8).  
The secreted proteins were quantified in pairwise manner (Figure 1-1). As 
a result, application of the quantitation criteria (50% detection and p-value < 0.05) 
in comparison sets 1 (BV2 versus C8D1A), 2 (C8D1A versus HT22), and 3 (BV2 
versus HT22) yielded 848, 763, and 1044 quantified proteins, respectively (Figure 
1-9A). Further, these lists were filtered by analysis using SignalP, SecretomeP, 
Exocarta, and TMHMM. After removing the unannotated proteins using the 
bioinformatics tools and filtering with criteria (2-fold change in intensity between at 
least 2 biological replicates), 509, 418, and 596 proteins were considered as 
differentially expressed secretion proteins (DESPs) in 3 comparisons, respectively 




Figure 1-8. Principal component analysis (PCA) 
(A) PCA of protein expression values in the cell lines. Components 1 and 2 account 
for 74% of the data variation. (B) Proteins driving the separation are colored 





Figure 1-9. Label-free quantitation of identified secretion proteins  
(A) Number of proteins quantified based on 50% detection and p-value < 0.05 in the 
9 comparison sets. (B) Number of differentially expressed secretion proteins (DESPs) 
quantified using the filter criteria (2-fold change in at least 2 of 3 biological replicates) 




Clustering analysis and validation 
The LFQ values of the proteins that were identified from the 3 cell lines 
were analyzed by ANONA to determine the trends of changes in abundance in the 
secretome. The heat map identified proteins with statistically significant changes 
between cell lines (FDR < 0.05) after ANOVA, z-score normalization, and 
hierarchical clustering. The heat map and hierarchical clustering indicated that cells 
with disparate characteristics can be distinguished by their specific secreted 
proteome patterns. Particularly, two-way hierarchical clustering created 3 clusters of 
cell types and 6 clusters of protein expression patterns in the 3 cell lines (Figure 1-
10). The clustering results showed clear separation of the cell lines and the correct 
grouping of technical and biological replicates in each cell line. Furthermore, 
western blot analysis for validation of the quantified proteins showed the same 





Figure 1-10. Cluster analysis.  
Heat map and hierarchical clustering of differentially expressed secretion proteins 
(DESPs) after ANOVA of secreted proteins in the 3 cell lines. The six types of 






Figure 1-11. Western blot for validation of label-free quantitation 
(A) Immunoblotting for validation of label-free quantitation data. Four randomly 
selected proteins were subjected to western blot analysis. (B) The graphs describe 
the patterns of the intensities of proteins corresponding to the results of the immune 
blots. 
 
Gene ontology and pathway analysis 
To determine the altered biological processes and pathways that might 
characterize the 3 cell lines, I analyzed the DESPs with regard to GO terms and 
KEGG pathway, based on the category of protein expression clustering (Table 1-1 
and Figure 1-12). Notably, the 3 cell lines displayed secreted protein clusters that 
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were typical of the original functions of the cell type 5. For example, clusters of 
highly expressed proteins in HT22 cells (clusters 3 and 5) were enriched for the GO 
BP terms “Cellular protein localization” (p-value < 1.13E-36) and “Cell adhesion” 
(p-value < 4.5E-08). Clusters of highly expressed proteins in C8D1A cells (clusters 
2 and 6) were enriched for the GO BP terms “Generation of precursor metabolites 
and energy” (p-value < 3.58E-06) and “Extracellular structure organization” (p-
value < 1.46E-04). Finally, clusters of highly expressed proteins in BV2 cells 
(clusters 1 and 4) were enriched for the GO BP terms “Vesicle-mediated transport” 
(p-value < 1.00E-03) and “Translation” (p-value < 1.13E-36).  
Interestingly, KEGG pathway analysis showed that DESPs are closely 
related to functions that are mediated by neurons, astrocytes, and microglia, 
according to each expression cluster (Table 1-1).  For example, many proteins in 
cluster 4 were enriched in lysosomes (32 proteins), which are linked the function of 
microglia as immune defense cells in the CNS 2-3, 5. Also, several proteins in cluster 
5 that were enriched with regard to focal adhesion (28 proteins), ECM-receptor 
interaction (16 proteins), and adherens junction (8 proteins) are involved in synaptic 
transmission, plasticity, and development in neurons 43. In cluster 2, many glycolytic 
proteins were enriched in glycolysis/gluconeogenesis (10 proteins) and the citrate 












Figure 1-12. Pathway analysis 
Pathway analysis with KEGG and PANTHER databases was performed against putative secreted proteins that were significant by ANOVA 
between secretome of the 3 cell lines. Number of proteins is annotated against their functions. Yellow line indicates the negative logarithm p-value 
of the Benjamini-Hochberg FDR; hence, the annotated pathways can be significant
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Table 1-1. Summary of GO terms and KEGG pathway analysis 
 
 
TOP5 of GO BP terms  Count p-value TOP5 of KEGG Pathway Count p-value 
Cluster 1 
Translation 12 8.01E-06 Lysosome 8 6.60E-05 
Protein folding 7 1.94E-04 Aminoacyl-tRNA biosynthesis 5 4.48E-04 
tRNA aminoacylation for protein translation 5 2.37E-04 One carbon pool by folate 3 8.26E-03 
Cellular protein localization 9 8.13E-04 Oocyte meiosis 5 1.74E-02 
Vesicle-mediated transport 11 1.00E-03 Tight junction 5 2.83E-02 
Cluster 2 
Generation of precursor metabolites and 
energy 
15 3.58E-06 Glycolysis/Gluconeogenesis 10 6.032E-06 
Cellular component morphogenesis 17 5.78E-06 Citrate cycle (TCA cycle) 7 2.516E-05 
Coenzyme metabolic process 11 9.47E-06 Pyruvate metabolism 7 1.31E-04 
Alcohol catabolic process 8 1.32E-05 Arginine and proline metabolism 7 5.52E-04 
Cofactor metabolic process 12 1.36E-05 Fructose and mannose metabolism 6 7.14E-04 
Cluster 3 
Cellular protein localization 14 1.13E-36 Proteasome 13 4.001E-12 
Intracellular transport 16 4.68E-09 Terpenoid backbone biosynthesis 4 1.24E-03 
Vesicle-mediated transport 15 5.04E-06 
Valine, leucine, and isoleucine 
degradation 
4 3.59E-02 
Ribonucleoside monophosphate biosynthetic 
process 
4 4.90E-05 Lysosome 6 4.00E-02 
Protein localization 19 1.06E-04    
Cluster 4 
Translation 58 1.13E-36 Ribosome 33 2.574E-25 
Translational initiation 11 4.68E-09 Lysosome 32 8.282E-20 
tRNA aminoacylation 9 5.04E-06 Other glycan degradation 8 4.297E-07 
Regulation of cytoskeleton organization 11 6.00E-05 Glycosaminoglycan degradation 8 7.508E-06 
RNA splicing 15 6.17E-05 Aminoacyl-tRNA biosynthesis 9 6.982E-05 
Cluster 5 
Cell adhesion 31 4.5E-08 Focal adhesion 28 2.68E-13 
Vasculature development 20 7.91E-08 ECM-receptor interaction 16 1.48E-09 
Blood vessel development 19 2.74E-07 Proteasome 7 1.07E-03 
Extracellular structure organization 12 6.00E-05 Adherens junction 8 2.90E-03 
Regulation of cell-substrate adhesion 7 6.17E-05 Pathways in cancer 18 3.01E-03 
Cluster 6 
Extracellular structure organization 7 1.46E-04 Proteasome 5 3.52E-04 
Macromolecule catabolic process 12 6.90E-04    
Proteolysis involved in cellular protein 
catabolic  
10 2.16E-03    
Cell adhesion 10 3.01E-03    
Proteolysis 14 3.16E-03    




This report is the most comprehensive secretome study of murine neurons, 
astrocytes, and microglia to date, in which 2795 protein groups and 2125 putative 
secreted proteins were identified in 27 LC-MS/MS runs. Hundreds of DEPs and 
DESPs were discovered in the cell lines by LFQ approach. In addition, many PTMs 
were identified in the secreted proteins. Moreover, our datasets in CMs of 3 cell lines 
have provided exclusively secreted proteins that have not been reported to date. Our 
proteome covered 58% to 94 % of proteome that obtained from previous proteomic 
studies using astrocyte, microglial, and neuron primary cells (Figure 1-13). It 
suggests that our data is appropriate for the applications as in vitro model alternative 
to in vivo model. Specifically, I identified 49 proteins, including cytokines, hormones, 
and growth factors, 27 of which were quantified as DESPs, implicating them as 
important modulators of communication between the nervous and immune systems 
(Table 1-2).  
Further, extensive profiling with our secretome approach provided standard 
reference libraries of secreted proteins in cultured neurons, astrocytes, and microglia, 
which will be invaluable for future functional studies of the molecular mechanisms 
of cell-cell communication in the CNS and brain. Thus, our approach can be used to 
perform in-depth quantitative proteomics studies of brain functions and the 
pathogenesis of neurodegenerative diseases with deep proteomic coverage. 
Improving the quantitation of the DESPs, the HCD spectra libraries from our large 
secretome datasets can be used to perform targeted proteomic analyses, including 
multiple reaction monitoring (MRM) and parallelreaction monitoring (PRM), 
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constituting a valuable resource for targeted quantitative studies of proteins that are 
related to cell-cell communication and dysfunction in the response to many CNS 
pathologies.  
 
Figure 1-13. Comparison our data with others reported in the literature. 
Identified and putative secreted proteins from our dataset were compared with other 
studies in CMs of (A) astrocyte 7, 44, (B) microglial 45, and (C) neuron 46-47. The 
number in parentheses indicates number of putative secretion proteins analyzed by 
tools such as SignalP, SecretomeP, TMHMM, or Exocarta. (D) The secretome 
coverage indicates portion of secreted proteins identified from this study compared 
to previous proteomic studies of primary CNS cells. 
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Subtitle: Quantitative proteomics reveal temporal proteomic 
changes in signaling pathways during BV2 mouse microglial 
cell activation 
 
METERIALS AND METHODS 
Cell line culture and treatments 
 BV2 mouse microglial cells were cultured in DMEM, containing 10% FBS 
and 1% penicillin and streptomycin. A 100-mm dish was seeded with 1x106 cells. 
After a 24-hr incubation at 37°C with 5% CO2, serum deprivation was performed 
with serum-free media, and the cells were allowed to adjust for at least 4 hr. In the 
control sample, pellets were scraped and washed 3 times with 1x DPBS, and the 
conditioned media was collected and concentrated on 3 kDa conical filters for 24 hr 
(Amicon Ultra, Merck Millipore, Darmstadt, Germany) to a volume of 
approximately 200 l 48.  
BV2 cells were plated in a 100-mm dish and exposed to 1 of 2 stimuli for 
24 hrs: 1 g/ml Escherichia coli LPS or 10 ng/ml IFN-γ that was dissolved in serum-
free DMEM. In case of the targeted analysis stage, BV2 cells were activated with 1 
g/ml LPS, 10 ng/ml IFN-γ, or 1 g/ml LPS plus 10 ng/ml IFN-γ for 6, 12, 24, and 
48 hr. At each time point, the conditioned media and pellet were harvested as in the 
control sample. All treatments were performed in triplicate.  
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Protein isolation and digestion 
Cell pellets were lysed at room temperature in lysis buffer (4% SDS, 1 mM 
DTT, 0.1 M Tris-Cl, pH7.4) with 1 min of sonication. Conditioned media was added 
to the lysis buffer (4% SDS, 2 mM DTT, 0.1 M Tris-Cl), and the lysates were boiled 
and centrifuged at 15,000 rpm for 10 min. The concentration of the proteins in the 
lysates was measured using a BCA assay kit (Thermo Fisher Scientific, IL, USA). 
Then, 200 g of the protein sample was digested by filter-aided sample preparation 
(FASP) with slight modifications 49. The proteins were loaded onto a 30 K spin filter 
(Millipore, Billerica, MA, USA), and the buffer was exchanged with UA solution (8 
M urea in 0.1 M Tris-Cl, pH 8.5) by centrifugation. After triple UA exchange, the 
reduced cysteines were alkylated with 0.05 M iodoacetamide (IAA) in UA solution 
for 30 min at room temperature in a dark room. I exchanged the UA buffer to 40 mM 
ammonium bicarbonate (ABC) and digested the samples with trypsin (enzyme-to-
substrate ratio of 1:100) at 37°C for 18 hr. For of the construction library and the 
targeted analysis, the digested peptides were acidified with trifluoroacetic acid and 
cleaned using homemade C18 Stage-Tip columns. 
 
Stable-isotope dimethyl labeling and cleaning of peptides 
Dimethyl triplex labeling was performed according to standard protocols 
with several modifications 50. Digested peptides were loaded onto a 200-l 
homemade C18 Stage-Tip column that was packed with POROS 20 R2 resin. The 
peptides were then tagged with stable-isotope dimethyl labels, comprising 3 
mixtures: regular formaldehyde and cyanoborohydride (28-Da shift, designated 
‘light label’), deuterated formaldehyde and regular cyanoborohydride (32-Da shift, 
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designated ‘intermediate label’), and deuterated and 13C labeled formaldehyde with 
cyanoborodeuteride (36-Da shift, designated ‘heavy label). I flowed the dimethyl 
labels intermittently through the column 5 times for 10 mins. The labeled peptides 
were then washed with loading buffer that contained 0.1% TFA. Cleaned peptides 
were eluted and dried on a vacuum concentrator. 
Three biological replicates were established for each treatment group: 2 for 
the “forward” experiment and 1 for the “reverse” experiment. For the forward 
experiment, untreated control peptides were labeled with the light label, whereas 
peptides from cells that were stimulated with LPS or LPS+IFN-γ were labeled with 
the intermediate or heavy label, respectively. For the reverse experiment, LPS treated 
samples were tagged with heavy dimethyl labels, and the control and LPS+IFN-γ 
treated samples were tagged with light and intermediate dimethyl labels, respectively. 
 
Peptide fractionation with high-pH reverse phase fractionation 
Dimethyl-labeled peptides were fractionated per an established StageTip-
based high-pH reverse phase protocol with some modifications 6. Dimethyl-labeled 
peptides and desalted peptides were resolved in 200 l loading buffer (10 mM 
ammonium formate, pH 10 and 2% acetonitrile) and loaded onto 200-l yellow tips 
that were packed with C18 Empore disk membranes (3 M, Bracknell, UK) and 
POROS 20 R2 resin (Invitrogen, Carlsbad, CA). Loaded peptides were eluted with 
ACN gradient buffer solution at pH 10 in 13 fractions. The fractions were dried on 





Mass spectrometric analysis of dimethyl labeling  
Peptides were separated on a Nanoflow Easy-nLC 1000 (Proxeon 
Biosystems, Odense, Denmark) that was equipped with a trap column (100 Å , 3-m 
particle, 75 m x 2 cm) and an analytical column (100 Å , 1.8-m particle, 50 mm x 
15 cm). A gradient that ranged from 5% to 30% acetonitrile was run at a fixed flow 
rate of 300 nl/min for 180 min and 60 min for the relative quantitation and targeted 
analysis, respectively. Eluted peptides were ionized at the tip of the column at a spray 
voltage of 2.00 kV. Ionized peptides were analyzed on a quadrupole-orbitrap mass 
spectrometer (Q-Exactive, Thermo Fisher Scientific, San Jose, CA, USA). 
MS1 spectra were measured in data-dependent acquisition (DDA) mode at 
a resolution of 70,000 with an m/z range of 300 to 1800 and a target automatic gain 
control (AGC) of 3.0 x E6 with 100-ms maximum fill times. The 20 most abundant 
ions were selected with an isolation window of 2 m/z, fragmented by higher-energy 
collisional dissociation (HCD) with a normalized collision energy of 30 and a 
resolution of 17,500 at 100 m/z. The dynamic exclusion of sequenced peptides was 
fixed to 30 s to restrict repeated sequencing. Each sample was analyzed in triplicate 
for technical replicates. 
 
Mass spectrometry for label-free PRM analysis 
The experiments were performed on a quadrupole mass filter that was 
connected to a benchtop orbitrap mass spectrometer in parallel reaction monitoring 
(PRM) mode with an isolation width of 2 m/z, a target AGC value of 1.0 x E6, and 
a maximum injection time of 100 ms.  To optimize the PRM analyses, the PRM 
event used a resolution of 35,000 or 70,000 on the orbitrap. Ion 
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activation/dissociation was performed with a higher-energy c-trap dissociation of 25, 
27, or 30. For regular PRM analyses, the PRM event used a resolving power of 
35,000 with a normalized collision energy of 27 on the orbitrap. PRM scans were 
triggered by scheduled targeting precursor ions that were selected for endogenous 
peptides in ±5-min and ±1.5-min elution windows for the evaluation of detectability 
and the targeting method, respectively 
 
Raw data search  
Raw MS files for the dimethyl-labeled quantification were processed using 
the Andromeda search engine, the built-in peptide identification algorithm in 
MaxQuant (ver. 1.3.0.5), to match the spectra against the UniprotKB FASTA 
database (74,540 entries, version from June 2014). MS/MS searches were performed 
with the following parameters: peptide length of at least 6 amino acids, fixed 
carbamidomethylation modification, variable methionine oxidation, and variable N-
terminal acetylation. The tolerance was set to 6 ppm and 20 ppm for main search and 
first search, respectively. A false discovery rate (FDR) of 1% was applied to all 
protein and peptide searches. The retention times of all analyzed samples were 
linearized with the “Match between runs” feature of MaxQuant, which allows 
identified peptides to be transferred in the absence of sequencing with a retention 
window of 2 min. Only for the dimethyl labeled quantification were 3 multiplicities 
selected with stable-isotope dimethyl labeling (control: +28 Da, intermediate: +32 
Da, heavy: +36 Da) at the lysine and N-terminus. All proteins were filtered for 




Prediction tools for putative secreted proteins 
 Proteins that were detected in conditioned media were filtered to predict 
secreted proteins using SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/), 
SecretomeP 2.0 (http://www. cbs.dtu.dk/services/ SecretomeP/), and the TMHMM 
server 2.0 (http://www.cbs.dtu.dk/services/TMHMM/) and by comparison with the 
Exocarta database (http://www.exocarta.org). The FASTA forms of the identified 
proteins were exported and used for this analysis. The resulting protein lists were 
submitted to the SignalP 4.1 server. ‘Eukaryotic organism group’ and a cutoff value 
of 0.45 were used as prediction parameters. The SecretomeP 2.0 server was used to 
determine whether the proteins were non-classically secreted, with the organism 
‘mammal’ and a threshold score of 0.5 as parameters. The TMHMM server 2.0 was 
used with the FASTA forms to predict transmembrane helices in the proteins. The 
resulting dataset was compared with exosomal proteins from Exocarta.  
 
Detectability of label-free PRM analysis 
The necessary information on the target peptides, such as RT, precursor m/z, 
and precursor charge, was extracted from the reference spectral libraries to initiate 
the PRM. To match the raw data from the PRM, iRT peptides that contained heavy 
isotopes (13C6, 15N7 in Arg or Lys) were spiked into each sample at equal amounts 
(25 fmol). The elution times of the 15 iRT peptides in each sample were used to 
calibrate and align the retention times of the target peptides. (Thermo Fisher 
Scientific, IL, USA). Applying linear regression to the elution times corrected the 
time shifts that were caused by the changes to the system parameters and the long 
intervals between analyses 51. The adjusted elution times of each peptide were used 
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to determine the centers of the monitoring windows more accurately for the 
scheduled LC-MS/MS analyses. MS analysis was performed without scheduling of 
retention time for the detectability check. The assigned peptides were manually 
accepted only if they satisfied the empirically defined criteria: presentation spectrum 
in the, non-redundant peptide, selected top 5 or fewer product ions, and CVs of 
retention times < 5%. 
 
Reproducibility of label-free PRM analysis 
Detectable peptides were embedded into a single analyst inclusion list of 
the method file. The list contained 525 and 604 peptides for the WCP and SEC 
groups, respectively. The peptides were analyzed in windows of 4 minutes with 5 
technical replicates for each run. To check the reproducibility of each run, high-
purity (>98%) stable-isotope-labeled b-galactosidase peptide (GDFQFNISR, AQUA 
ultimate, Thermo Fisher Scientific, IL, USA), with 13C6, 15N7 in Arg, was spiked into 
PRM samples. Extracted-ion chromatograms (XICs) of the b-galactosidase peptide 
were used to normalize the results with regard to the variation between runs. 
Normalized XICs of select product ions were calculated using Skyline against target 
peptides. Peptides with CVs < 20% in 5 replicates under at least 2 conditions were 





In-house spectral library for PRM analysis 
A spectral library with high-quality reference MS/MS spectra is necessary 
to identify false positives in MS/MS spectra that are obtained in the PRM, because 
all fragments of the targeted peptide were acquired in the PRM analysis. Comparing 
spectra with the annotated reference MS/MS spectra confirms the correct identity of 
the peptides in the targeted analysis. Two search engines were used to increase the 
spectral resources in constructing the PRM library. The spectra were first identified 
using the Andromeda search engine in MaxQuant. The parameters in the discovery 
stage were used, except for those that pertained to the labeled quantification. The 
built-in SequestHT search algorithm in Proteome Discoverer (ver 1.4, Thermo Fisher 
Scientific, San Jose, CA, USA) was used to construct the second library. A 
microglia-specific library of 76,910 peptides was constructed—corresponding to 
6329 proteins and 914,829 MS/MS spectra—identified from 12 pre-fractionated 
pooled matrix samples. 
 
Target protein selection and in silico fragmentation 
Target selections in the whole cell proteome (WCP) and secretome (SEC) 
groups were processed as shown in Figure 2-6 A. Normalized ratios from MaxQuant 
were filtered statistically in 2 steps: (1) Two paired groups were compared by their 
significance B values, which were calculated for the protein subsets that were 
obtained, based on intensity, with a Benjamini-Hochberg FDR < 5%. (2) ANOVA 
with p-value<0.05 was then applied to proteins that passed the first step to select 
significantly differentially expressed proteins (DEPs) or differentially expressed 
secreted proteins (DESPs) in the 3 conditions.  
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To compare our whole-cell lysate data with earlier studies on the BV2 
proteome and transcriptome, KEGG pathway analysis was performed using Mus 
musculus as the reference with default settings on the DAVID bioinformatics website 
(Ver 6.7, https://david-d.ncifcrf.gov/) with DEPs. Protein-protein interaction 
networks were searched with associated proteins in the KEGG pathways using 
Cytoscape and the STRING database 52-53.  
For the label-free PRM method, endogenous peptides must first be selected 
for quantifiable surrogates of a target protein. Because multiple MS/MS data points 
for the selected precursor are acquired throughout the elution profile, the peptide 
should be stoichiometric and specific for the target protein. The mass range of the 
quadrupole orbitrap instrument was suitable for m/z values of peptides with 6 to 25 
amino acids. The selected peptide should be unique to the target protein. Unique 
peptides were identified, based on the MaxQuant results. A double or triple charge 
state of a peptide was preferred to optimize the measurable m/z range. The signals 
of the less than five most intense product ions for each precursor were selected, based 
on being matched in the library to a portion of the product ion on normalization of 
the peak areas to total peak areas. 
 
Target peptide quantification and processing of longitudinal datasets 
Raw files from the longitudinal PRM analysis were processed using Skyline 
(ver. 3.5.0), an open source software for quantitative proteomic analysis 54. Because 
reproducibility of the peptide elution time is critical when the sample size is large, 
commercial iRT peptides were added to the sample before data were acquired. Peak 
integration was performed by manually drawing a demarcation line, based on the RT 
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prediction. After a .csv file that contained variables, such as protein name, sequence 
of peptide, charge, condition, and the normalized extracted-ion chromatogram (XIC) 
of the peak area, was exported, it was imported into MSstats (ver. 3.3.4), an R 
package that is used for the relative quantification of proteins and peptides. The data 
were processed using a log2 scale and then normalized to equalized medians. A linear 
mixed model was used to calculate the degree of statistical significance of the 
integrated peak area between the 3 conditions. Twelve comparisons of the 3 
conditions were made simultaneously. 
 
NO assay of conditioned media from activated microglia 
Nitric oxide assay was performed on the conditioned media of activated 
microglia using Griess reagent 55. Griess reagent (50 l) was mixed with NaNO (0-
100 M) to create a standard NO curve. After a 15-min incubation, the absorbance 




 Whole-cell lysates were prepared in RIPA lysis buffer (Tris-Cl pH 7.4, 1% 
NP-40, 1 mM EDTA, 8 M urea, and 150 mM NaCl) that contained protease inhibitor 
cocktail (PMSF). Proteins (30 g, as measured by BCA assay) were separated by 
12% SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes 
(Hybond-P, GE Healthcare, PA, USA). Membranes were blocked with 5% BSA and 
incubated for 2 hours with primary antibody to β-actin or iNOS (1:1000 dilution; 
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Sigma-Aldrich, Louis, MO, USA) for 18 hours at 4°C. The membranes were then 
washed 5 times with Tris-buffered saline and Tween-20 (TBS-T) before being 
incubated in horseradish peroxidase-conjugated secondary antibodies for 2 hr. 
Detection solution (West-Q chemiluminescent substrate Kit-plus, GenDEPOT, 
Barker, TX, USA) was used to develop the membranes, and the signals were 





Activation status of murine microglia cell line 
 Prior to the mass spectrometric analysis, the status of activated microglia 
was assessed and confirmed in whole-cell proteome (WCP) and conditioned media 
collection (CMC) samples by NO assay and immunoassay of inducible nitric oxide 
synthase (iNOS), respectively (Figure 2-1). LPS/IFN-γ treated microglia expressed 
more iNOS than cells that were stimulated with LPS alone. Secretion of NO also 
rose with the combination treatment. In longitudinally collected samples, NO and 
iNOS levels increased at each time point. These results demonstrate that LPS and 
IFN-γ effect the production of nitric oxide through inducible nitric oxide synthase 
and synergize in activating this murine microglial cell line compared with either 
individual compound. To determine the mechanisms that affect the intracellular and 
intercellular environments during microglial activation, experiments were conducted 







Figure 2-1. Confirmation of differential expression of iNOS and nitric oxide in 
activated microglia model. 
(A) NO assay and (C) immunoblotting were performed to measure nitric oxide 
in conditioned media and iNOS in whole-cell lysate collected from 3 
treatment groups: control, LPS, and LPS plus IFN-γ. These samples were 
used for the discovery step. Longitudinal samples were collected for 6, 12, 
24, and 48 hr from control, LPS treated, IFN-γ treated, and LPS plus IFN-γ 
treated groups. (B) NO assay and (D) immunoblotting were performed with 





Figure 2-2. Systematic workflow of proteomic analysis for whole-cell and 
secreted proteomes in activated microglia cell line. 
A single platform workflow enabled both global proteomics and targeted proteomics 
in this study. In-depth quantitative proteomic analysis discovered intracellular and 
extracellular proteins of activated BV2 microglia cells in large scale. A number of 
filtration criteria starting with a pairwise statistical testing and bioinformatics 
analysis were utilized to select target proteins. The longitudinal validation studies 
contained biological and technical triplicates using label-free PRM approach. 
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Characterization of proteome identified in discovery phase 
To examine the global protein expression profiles on activated BV2 
microglia cells, quantitative proteomics was performed by stable-isotope dimethyl 
labeling. Based on the discovery analysis, 5492 protein groups were identified in the 
WCP, of which 4748 proteins were quantified in the LPS or LPS/IFN-γ treated group 
across the 3 biological replicates (Figure 2-3A). From the corresponding CMC, 4938 
protein groups were identified, and 3558 proteins were quantified in the LPS  and 
LPS/IFN-γ treated groups in biological triplicate (Figure 2-3B). Specifically, to 
predict the putative secretome, 3558 quantifiable proteins in CMC were examined 
by sequence analysis with SignalP, SecretomeP, Exocarta, and TMHMM 48 (Figure 
2-3C). As a result, 2387 proteins (67.09% of quantified proteins) were expected to 
be released by classical or non-classical secretion from activated cells and were thus 
collectively termed the secretome (SEC). The quantified proteins in the WCP and 






Figure 2-3. Identification and quantification for dimethyl labeling. 
Venn diagram of identified and quantified proteins in (A) whole-cell proteome and 
(B) conditioned media from dimethyl-labeled discovery proteomics. Proteins that 
had a minimum ratio count of two were selected as quantified proteins. (C) Four 
bioinformatics tools, SignalP, SecretomeP, Exocarta, and TMHMM were used for 
the prediction of putative secreted proteins. The number in each box indicates the 
amount of putative secreted proteins from the prediction tools. (D) Box-plots and 
minimum to maximum whiskers representing the CV values of technical and 
biological replicates in the WCP and SEC groups for the discovery data. Box and 
whisker plots with statistical summaries were calculated in MedCalc (Ver. 12.3.0.0).  
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Global protein quantification in activated microglia 
Principal component analysis (PCA) was performed to compare the 
proteomes of normal microglia and each group of activated microglia. The distance 
between each group was 80.3% for the WCP group and 75.3% for the SEC group. 
These values were calculated, based on the sum of the components from the analysis 
(Figure 2-4 A, B). To evaluate the reproducibility and quality of the dimethyl labels, 
their coefficient of variation (CV) and Pearson correlation values were calculated. 
The median CVs between the technical and biological replicates of the quantification 
of dimethyl labeling for the WCP group were 4.09% and 10.54%, respectively. For 
the SEC group, the CVs were 4.33% and 10.79%, respectively (Figure 2-3D). The 
median CVs in all samples were below 20%, indicating that the quantification of 
dimethyl labeling had high reproducibility. Forward and reverse labeling was 
performed in each group to reduce potential errors. By Pearson correlation analysis 
of the forward and reverse experiments under each condition, there was significant 
correlation, with R values of 0.823 and 0.843 for the LPS and LPS/IFN-γ treatments 
in the WCP group, respectively. For the SEC group, these values were 0.87 and 0.913, 
respectively (Figure 2-4 C, D).  
On examination of the dimethyl isotope labeling across biological and 
technical triplicates, I observed high correlation between the control and LPS treated 
groups (0.92-0.96). In contrast, the correlation was low between the control and 
combination treatment group (0.86-0.91, Figure 2-5). This difference indicates that 






Figure 2-4. Assessment of global proteomics 
Principle components analysis (PCA) of the (A) whole-cell proteome and (B) 
secretome in the dimethyl-labeled quantitative analysis revealed that each ratio of 
biological labeling was similar, except for the reverse labeling of a third biological 
replicate. Components 1 and 2 accounted for 80.3% and 75.3% of the variation in 
data in the WCP and SEC groups, respectively. PCA test was performed in Perseus 
(Ver. 1.5.0.8). Correlations between the forward and reverse labeling of dimethyl 





Figure 2-5. Heatmap of pairwise correlation values for discovery data 
The numbers in orange or green triangle represent pairwise Pearson correlation 
values for WCP or SEC groups, respectively. Pearson correlation coefficients 
between samples in the discovery data were calculated using Perseus, and the 




Significance of proteome between treatment groups 
To identify differentially expressed proteins (DEPs), a pairwise comparison 
analysis was performed for each treatment group. Expression levels of whole-cell 
and secreted proteins in the LPS  and LPS/IFN-γ treated groups were measured and 
compared with that of unactivated microglia. The statistical analysis for significant 
expression and secreted proteins was performed as described in Figure 2-6 A.  
For the WCP group, significantly expressed proteins were determined by 
significance B analysis (Benjamini-Hochberg FDR<0.05) and pairwise comparison 
257 proteins in control versus LPS treated cells and 264 proteins from LPS/IFN-γ 
treated cells were significant. Subsequently, ANOVA was performed for proteins 
that were significantly expressed in at least 2 of the 3 pairwise comparisons for each 
condition. Total of 202 proteins were considered DEPs between the 3 groups, with 
p-value < 0.05.  
Using 202 DEPs from the discovery stage, KEGG pathway enrichment was 
performed to classify functions that were associated with the activation of microglia 
(Figure 2-7 A). Five distinct pathways that were related to microglial activation were 
selected: glycolysis and gluconeogenesis; antigen processing and presentation; Toll-
like receptor signaling; natural killer cell-mediated cytotoxicity; and alanine, 
aspartate, and glutamate metabolism. To analyze proteins that were involved in these 
pathways and DEPs, direct and indirect information on protein-protein interactions 
(PPIs), based on the STRING database, was used to select additional target proteins 
(Figure 2-6 B). Ultimately, 319 proteins were chosen as initial target proteins from 




Figure 2-6. Scheme for target protein selection 
(A) Criteria for target proteins in the global proteomics analysis are described in the 
flowchart. Two statistical analysis methods, significance B and ANOVA, were 
performed using Perseus. (B) Additional target candidates were collected using the 
STING database, which describes interacting or bound proteins. The protein-protein 
interaction (PPI) network was imported into Cytoscape, ver 3.4.0, and the proteins 
were visualized and mapped into KEGG pathways. Significantly differentially 
expressed proteins (diamond box in the figure) were enriched in 5 KEGG pathways 




Figure 2-7. Statistical analysis and bioinformatics. 
Hierarchical heatmap clusters of significant proteins from ANOVA across 3 
treatment groups were analyzed in Perseus (Ver. 1.5.0.8); 202 and 135 proteins were 
included in the (A) WCP and (B) SEC groups, respectively, with a Benjamini-
Hochberg FDR <0.05. DEPs and DESPs were analyzed for gene ontology and 
KEGG pathway annotation on the DAVID website. Minus log2 p-values with count 
of enriched proteins were drawn using Excel (BR: biological replicate).  
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The SEC group was processed in the same manner as the WCP group. By 
significance B analysis, 212 and 153 proteins were significant by pairwise 
comparison in control versus LPS and control versus LPS/IFN-γ treated groups, 
respectively. By ANOVA of the 3 groups, 135 secreted proteins were significantly 
differently expressed secreted proteins (DESPs). Because the KEGG pathway 
analysis of DESPs identified the enrichment of 2 pathways, “nicotinate and 
nicotinamide metabolism” and “ribosome”, I designated 135 DESPs as target 
proteins, with an additional 35 cytokines that mediate cell-cell communication but 
were not quantified in the dimethyl labeling proteomic analysis. These cytokines 
included common cell surface markers on activated microglia and small inducible 
cytokines, such as tumor necrosis factor and C-C motif chemokine ligands. In 
conclusion, 170 putative secreted proteins were defined as initial target proteins for 
the PRM analysis. Consequently, PRM analysis was used to validate the 
quantification of target proteins from discovery-based proteomics studies and to 






Selection of target peptides 
 To select target peptides from initial target proteins, Skyline was processed 
with the necessary information from the spectral library. The number of target 
peptides was 1086 and 1088, corresponding to 319 and 170 proteins, for the WCP 
and SEC groups, respectively. RT alignment was performed by spiking with the iRT 
SIS peptide, and matching elution times for the selected peptide and predicted 
retention times based on iRT score from the Skyline calculation were the criteria to 
pare the number of undetectable peptides (Figure 2-8 A). After optimization of the 
resolving power and collision energy for MS2 for the quality control, an intra-
technical assay with 5 replicates in each group was performed to select target 
peptides that had a CV < 20% (Figure 2-8 B, C) by increasing the quantitative 
reliability, I hoped to improve the reliability of the target screen. Using these criteria, 
347 and 464 target peptides, corresponding to 217 and 146 proteins of the whole-cell 
proteome and secretome, respectively, were selected for the longitudinal activation 




Figure 2-8. Filter criteria of targeted peptides for label-free PRM 
Filter criteria were applied sequentially to select quantifiable target peptides for 
label-free PRM analysis (A). To check the quality of the analyte peptide, the CVs of 
5 replicates in each treatment group were measured in the (B) WCP and (C) SEC 
groups. Box and whisker plots with statistical summaries were calculated in 













LPELLLK 2 b4, b3, y5, y6
TFEDFVR 2 y3, y4, y5
LGGIPVGVVAVETR 2 y5, y7, y8, y10
2 Q8R5C9 Acacb STRING DB FGAYIVDGLR 2 b3, y3, y5, y6
GIAFEDVR 2 b5, y4, y5, y6
ENVLIGEGAGFK 2 y3, y5, y7, y9
GATPYGGVK 2 y3, y4, y6
FASEITPITISVK 2 y3, y5, y7, y8
VAVLSQNR 2 y4, y5, y6
ELGLNPEK 2 y3, y6
6 P56376 Acyp1 STRING DB GTVQGQLQGPVSK 2 y5, y7, y9
AGDTVIPLYIPQC[+57]GEC[+57]K 2 b5, y5, y7, y11
IDPSAPLDK 2 b3, y3, y4, y6
LGPAPVPVGPLSPESR 2 b3, y8, y10, y12
LLQALGLSPGSGK 2 y5, y6, y8, y9
VAGTQAC[+57]ATETIDTNR 2 y3, y8, y9, y10
ALGLSNFNSR 2 y4, y6, y8
GLEVTAYSPLGSSDR 2 b3, y8, y9, y11
10 P45376 Akr1b1 STRING DB NLVVIPK 2 b3, y3, y5




GYFIQPTVFGDVK 2 b3, y4, y5, y8
YLAPTILTDVDPNSK 2 b4, y4, y8, y9




LVPALQNAITR 2 y6, y7, y8, y9




FQDEEEVFEWNNEVK 2 b3, y6
VEPVDASGTEK 2 y4, y5, y6, y7
C[+57]QVLLEAAR 2 y5, y6, y7
ISFTGSVPTGVK 2 y5, y8, y9
QLLLTADDR 2 y4, y5, y6, y7








TPSALAILENANVLAR 2 y8, y10, y11
21 Q8JZV7 Amdhd2 STRING DB VLPQIPVK 2 y3, y4, y5, y6
22 P35991 Btk STRING DB LSYYEYDFER 2 y4, y5, y6, y7
LSEEVSELELR 2 y6, y7, y8, y9
EASIYDLTSYFTGSK 2 y4, y5, y8, y11
VFPALSTLDLSDNPELGER 3 y4, y6, y7, y9




GTSQTNVIC[+57]GLK 2 y4, y5, y7, y8
26 P60766 Cdc42 STRING DB TC[+57]LLISYTTNK 2 b3, y4, y6, y7
27 P61022 Chp1 STRING DB IPELAINPLGDR 2 y6, y8, y9, y10
28 Q60680 Chuk STRING DB IIDLGYAK 2 y4, y5
29 Q9JKF4 Clec6a STRING DB WQWIDDTPFSQNVR 2 y7, y8, y10, y12
30 Q01149 Col1a2 STRING DB GFPGTPGLPGFK 3 b3, y3, y4
31 O88587 Comt STRING DB AVYQGPGSSPVK 2 b3, y3, y7, y8
GLVYETSVLDPDEGIR 3 y4, y5, y6, y7
GYSIPEC[+57]QK 2 b3, y3, y4, y5
33 Q61462 Cyba STRING DB LFGPLTR 2 y3, y4, y5
YSIALSDIGDNENEEYLNFAR 3 y6, y7
NPEGGLYVAVTR 2 y5, y6, y9, y10
QSISNSESGPR 2 y4, y6, y7, y8
35 Q6Q899 Ddx58 STRING DB IESFVVEDIVSGVQNR 2 y7, y8, y10, y11
























































DVPLGAPLC[+57]IIVEK 2 y3, y4, y8, y10








GVPLYR 2 y3, y4
ADAVYTGLNTR 2 b3, y5, y6, y7
SQETYETLK 2 y3, y5, y6, y7
41 P26151 Fcgr1 STRING DB ELFTTPVLR 2 y4, y5, y6, y7
42 P08508 Fcgr3 STRING DB LDPPWIQVLK 2 y5, y6, y7, y8




GSLLDFLK 2 y3, y4, y5, y6
45 P16858 Gapdh STRING DB VIPELNGK 2 y3, y5, y6
DC[+57]PVSSYNEWDPLEEVIVGR 3 y5, y6, y7, y9
AENAC[+57]VPPFTVEVK 2 b4, b3, y7, y8
FVTTEFEPC[+57]FDAADFIR 3 y3, y6, y7, y8
VIFLEDDDVAAVVDGR 2 y8, y9, y10, y11




GYDVDFPR 2 y3, y6
49 Q9WU65 Gk2 STRING DB FLVFNSK 2 y4, y5
50 P23780 Glb1 STRING DB TVAEALGILC[+57]PNGPVK 2 y6, y7, y8, y10
51 P30677 Gna14 STRING DB FVFAAVK 2 y3, y4, y5
52 P21279 Gnaq STRING DB VSAFENPYVDAIK 2 y4, y7, y8
53 P63213 Gng2 STRING DB EDPLLTPVPASENPFR 3 y6, y7, y8
54 Q9JK38 Gnpnat1 STRING DB VEDVVVSDEC[+57]R 2 b3, y6, y7
TLASLSPETSLFIIASK 3 y3, y4, y5, y6
EWFLEAAK 2 y3, y4, y5
56 Q60631 Grb2 STRING DB NQQIFLR 2 y3, y4, y5
57 P10649 Gstm1 STRING DB YIATPIFSK 2 y3, y5, y6, y7
58 O09131 Gsto1 STRING DB VPPLIASFVR 2 y5, y6, y7, y8
FEDGDLTLYQSNAILR 2 y6, y8, y9, y10
SLGLYGK 2 y3, y4, y5
GIDYEIVPINLIK 2 b3, y4, y6, y7
VITSGFNALEK 2 y3, y7, y8, y9
61 Q61425 Hadh STRING DB LLVPYLIEAVR 2 y5, y6, y7, y8




GAALITAVGVR 2 y3, y4, y5, y8
AELLFQGK 2 y3, y4, y5, y6
NVELVDGEEGR 2 y5, y6, y7, y9
GQDSPAPSVR 2 y4, y6, y7, y8
VAEGSVQIINQVYSIPEC[+57]R 3 y4, y6, y10
66 P63158 Hmgb1 STRING DB DIAAYR 2 y3, y4
LVVVGAGGVGK 2 y5, y7, y8, y9
QGVEDAFYTLVR 2 y6, y7, y8, y9
GEEILSR 2 b3, y3, y4, y5
LFC[+57]SLEGLFPASEAR 2 y6, y7, y9, y10
ALDDILNLK 2 y3, y4, y6, y7
ALELLPK 2 y3, y4
SLSC[+57]LGEELLK 2 y3, y4, y6, y7




AQVTSLLGELQESQSR 2 y7, y9, y11, y12
DLPLATENPR 2 y5, y6, y7, y8
LSLSETLFQR 2 y5, y7, y8
QAPVPVLGPTPR 2 y5, y6, y8, y10
73 P81122 Irs2 STRING DB ALTDLVSEGR 2 y4, y5
TEFTFLDYVK 2 y5, y6, y7, y8
LADVVVGAEGR 2 b4, y5, y6, y9




























































75 P05555 Itgam STRING DB FQLELPVK 2 y3, y4, y5, y6
76 Q9QXH4 Itgax STRING DB IQYFGQSLSGGQDLTR 2 y3, y8, y10, y12
SIANPEFDQR 2 y6, y7, y8
SAVGELSDDSSNVVQLIK 2 b3, y4, y5, y12












FPISISSEPC[+57]IR 2 y4, y7, y8, y9
INVLVLEAR 2 y4, y5, y6, y7
EIPVDAPWQAR 2 y5, y6, y7, y8
NLPSVPGLLK 2 y5, y6, y7, y8








TIWEVPER 2 b5, y4, y5, y6
GQPFDVGPR 2 y4, y5, y6, y7
EIQILLR 2 y3, y4, y5
86 P14152 Mdh1 STRING DB GEFITTVQQR 2 b3, y5, y6, y7
GYLGPEQLPDC[+57]LK 2 b5, y5, y6, y10
GC[+57]DVVVIPAGVPR 3 b3, y4, y5, y6
IQEAGTEVVK 2 y3, y6, y7, y8
88 Q91VS7 Mgst1 STRING DB VFANPEDC[+57]AGFGK 2 y4, y5, y6, y9




SLLDAWQGR 2 y4, y5, y6, y7
NNVADITGPIILQTYR 3 y4, y5, y6
AGEEITQAQR 2 y4, y5, y6, y7
TPEIFR 2 y3, y4, y5
AFVEGC[+57]AAK 2 y3, y5, y6, y7
AEALFDFTGNSK 2 b3, y5, y7, y8
AGDVIFLLSK 2 b3, y3, y5, y6
EDIALSYQDAEGDLVR 2 b3, y7, y11, y12
IC[+57]NYVGPAK 2 y4, y5, y7
TAGC[+57]VTGGEEIYLLC[+57]DK 2 y3, y4, y5, y12
GGDEVYLLC[+57]DK 2 b3, y3, y4, y6
ALLDYGVTADAR 2 y5, y7, y8, y9
AGAAAPELLQALLR 2 b4, b3, y6, y9
96 Q8CIZ9 Nox1 STRING DB NLLSFLR 2 y3, y4
SADAVSVIPVLQR 2 b3, y5, y6, y8
VYAYGLALK 2 b3, y3, y5, y7
SFGLPSIGR 2 b3, y5, y7
FLSDVYPDGFK 2 y3, y5, y6, y9
DTSYLFITGPEVVK 2 y5, y6, y7, y9
GFVDDIIQPSSTR 2 y5, y6, y7, y10
DTVPLLAGGAR 2 y5, y6, y7, y8
FDSEGQLR 2 y4, y5, y6
GTPLDTEVPLER 2 y4, y5, y8








VYFIYEGYQGLVDGGSNIVEAK 3 b3, y4, y9, y10
104 Q9DAK9 Phpt1 STRING DB NGYDC[+57]EC[+57]LGGGR 2 y6, y7, y8, y9
QLLLQFER 2 y3, y4, y5, y6
VPFSQEIK 2 y3, y5, y6, y7
SASESYTQSFQSR 2 y5, y6, y8, y9
106 Q8CBQ5 Pi4k2b STRING DB LVILDYIIR 2 y4, y5, y6, y7
DFLVIPSPVLVK 2 b3, y5, y7, y8















































































VLSEIFSPVLFR 2 y5, y6, y7, y10
112 Q9Z1T6 Pikfyve STRING DB ELVNWLIR 2 y3, y4, y5, y6
113 O70172 Pip4k2a STRING DB FGIDDQDFQNSLTR 2 y4, y6, y9
114 Q80XI4 Pip4k2b STRING DB FGIDDQDYQNSVTR 2 y5, y6, y7, y10
115 P70182 Pip5k1a STRING DB DC[+57]LVLQSFK 2 y3, y4, y5
116 P53657 Pklr STRING DB VFLAQK 2 y3, y4




DEAFDPFDK 2 y3, y4, y6
SESSTEAYIR 2 y4, y5, y7, y8
FDDVVQAIR 2 b3, y5, y6, y7




LFEVGGSPANTR 2 b9, y5, y7, y9
121 Q32M04 Prps1l1 STRING DB VTAVIPC[+57]FPYAR 2 b4, b3, y7, y8












AVLC[+57]PPPVK 2 y3, y4, y5, y6
GGDEIFLLC[+57]DK 2 y3, y4, y6, y7
FVLNDWEAR 2 y4, y6, y7
TTLIFQK 2 y3, y5
DGYYEADLC[+57]PDR 2 y5, y7, y8, y9
NSGSC[+57]LGGDEIFLLC[+57]DK 2 y3, y4, y6, y11
SAGSILGESSTEASK 2 b4, y7, y9, y10
LTDGVC[+57]SEPLPFTYLPR 2 y7, y9, y12
TC[+57]LLIVFSK 2 y3, y4, y5, y6
QVELALWDTAGQEDYDR 2 y7, y8, y10, y11
TVNLNLWDTAGQEEYDR 3 y4, y5, y7, y9
YLEC[+57]SALQQDGVK 2 y3, y6, y7, y9
ILLVGEPR 2 y4, y5, y6
WIPLINER 2 y3, y4, y5, y6
SFEYC[+57]AR 2 y4, y5
132 Q8JZN7 Rhot2 STRING DB SAFLQAFLGNSLGEAR 2 b3, y8, y10, y11




TQIDVPLSLK 2 y3, y5, y6, y8
135 P47968 Rpia STRING DB FGGEVELR 2 b3, y4, y6
VGIENFELLK 2 y3, y6, y7
VIDFGFAR 2 y4, y5, y6
EAISLVC[+57]EAVPGAK 2 y3, y4, y8, y9
ELFDDPSYVNIQNLDK 2 y7, y8, y11
138 P97797 Sirpa STRING DB EDVVFTC[+57]QVK 2 b3, y4, y5, y6




QLTLLESDLYR 2 y3, y5, y7, y9
141 Q64337 Sqstm1 STRING DB LTPTTPESSSTGTEDK 2 y7, y9, y11, y12
GAYC[+57]LSVSDFDNAK 2 y3, y7, y8
DAWEIPR 2 y3, y4, y5
DESEQTVLIGSK 2 y3, y4, y7, y8
WYAPEC[+57]INYYK 2 y4, y6, y8, y9







































LSSTWEGIQAGK 2 y3, y4, y6
ALAGC[+57]DFLTISPK 2 y3, y5, y6
TTEENPIFVTSR 2 y5, y7, y8, y9
LSSSQGTIESSLQDISSR 2 y4, y5, y10, y11
LDNLVAIFDINR 2 b3, y5, y7, y8
IIALDGDTK 2 y4, y5, y6, y7
148 Q99MX0 Tktl1 STRING DB LIESQIQTNK 2 y3, y4, y5, y8
149 Q6R5N8 Tlr13 STRING DB ILEPNSFSGLTNLR 2 y6, y11
EFSPGC[+57]FQTIGK 2 y4, y8, y9
LEPFIFDDQTSLR 2 y6, y8
FVDLSDNR 2 b3, y4, y6
AQSAVADWVYNELR 2 y7, y8, y9, y10






GDQLSAEVNLPK 2 b3, y7, y8
VVFEQTK 2 y3, y4, y5
VVLAYEPVWAIGTGK 3 y4, y5, y6, y7
IIYGGSVTGATC[+57]K 2 y6, y10, y11
154 P62984 Uba52 STRING DB EGIPPDQQR 2 y3, y4, y5, y6
155 Q91ZJ5 Ugp2 STRING DB SFENSLGINVPR 2 y4, y6, y9
156 Q63886 Ugt1a1 STRING DB IPQTVLWR 2 y4, y5, y6, y7
157 Q8VCW4 Unc93b1 STRING DB SVGWGNIFQLPFK 2 y3, y4, y6, y9
YC[+57]SQVESASK 2 y4, y6, y7, y8
AGAEGILTNR 2 y3, y4, y6, y7
SDGTYLVR 2 y3, y4, y5, y6
VTWDSAQVFDLAQTLR 2 y3, y6, y8, y9
EIIDLQQYK 2 y3, y5, y6, y7
LQAETELINR 2 y4, y6, y7, y8
IEAELQDIC[+57]NDVLELLDK 2 b4, b3, y6, y10
YLSEVASGENK 2 y5, y6, y7, y9








QELEVLGR 2 y4, y5, y6
SVDSGIYLDSSYK 2 y4, y5, y7, y11
SGTDVDAANLR 2 y5, y6, y7, y8
TIFESEFK 2 y3, y4, y5, y6












ATIDC[+57]AGILK 2 y4, y6, y7
YPLNC[+57]ADPTSER 2 y8, y9
VGQALLQGNTER 2 y6, y7, y9
GEPWTFLVR 2 y4, y5, y6, y7
DSNIPGSDYINANYVK 2 b3, y6, y8, y12
GLDC[+57]DIDIQK 2 y4, y5, y6, y8
LTITSQNLQLESLR 2 y6, y8, y10, y11
SGPLEYPQLK 2 y4, y5, y6, y7
FIPFPASAK 2 y3, y5, y6, y7




TPQIQVYSR 2 y4, y5, y6, y7
VAVLENQNK 2 y4, y5, y7




GSLSGWILSK 2 y3, y4, y6, y7
EQFLDGDAWTNR 3 b3, y3, y4
QIDNPDYK 2 y3, y4, y6
EQWSNC[+57]PTIGQIR 2 y4, y7, y8, y9











































































ENGGLDSEESYPYEAK 3 b5, y4, y7, y8
YIQLPFGDEDALK 2 b3, y3, y5, y9




DAGVIAGLNVLR 2 b3, y6, y7, y8
ITPSYVAFTPEGER 3 y3, y4, y5, y7
LTPEEIER 2 y3, y4, y5, y6
YESLTDPSK 2 b3, y3, y4, y7
IDIIPNPQER 2 b3, y4, y6, y7








VSLYYESLC[+57]GAC[+57]R 2 y5, y7, y8, y9
DYTGEDVTPENFLAVLR 2 y9, y10








VQELPLAR 2 b3, y5, y6
SNQQLVDIIEK 2 y3, y4, y5, y6
TVESEAASYLDQISR 2 y4, y6, y8, y10
LIISELR 2 y3, y4, y5
DGEEAGAYDGPR 2 y3, y7, y8, y9
DLLTAYYDVDYEK 3 y3, y4, y6
GTLDPVEK 2 y3, y4, y5, y6
VC[+57]NPIITK 2 y3, y5, y6
SFANEEGEAQK 2 y3, y5, y6, y9
GLVEFQDVSFAYPNQPK 3 y4, y5, y6, y7
ENIAYGLNR 2 y4, y5, y6, y7
ALVGGTASTSVVR 2 y6, y10, y11








QFAPSPNC[+57]NK 2 y3, y5, y6, y7
DFQLFYDGPR 2 y3, y5, y6, y7












QGQVEDEWYSLSGR 2 y5, y6, y10
NLQELDLSQNYLAR 2 y7, y8, y9, y10
SLTTLILK 2 y3, y4, y5, y6
GIEIPEVR 2 b3, y4, y5, y6
IDVSVEAASGGK 2 y4, y6, y7, y9
FPFAANSR 2 y4, y5, y6, y7
LVIITAGAR 2 y4, y5, y6, y7
VIGSGC[+57]NLDSAR 2 y3, y4, y8, y10
AAVPSIK 2 y3, y4, y5
YSLEPVAAELK 2 y4, y5, y7, y8




ALPFWNEEIVPQIK 3 y3, y4, y5, y6
DATNVGDEGGFAPNILENK 3 y3, y4, y6, y7
EALELLK 2 b3, y4, y5
SC[+57]NC[+57]LLLK 2 y3, y4, y5, y6
LEEGPPVTTVLTR 2 y6, y8, y9, y10
NFYGGNGIVGAQVPLGAGIALAC[+57]K 3 y3, y5, y9, y11











































































VVDLLATDADIVSR 2 b3, y6, y8, y9
VGIGAFPTEQDNEIGELLQTR 3 y4, y5, y7, y8
FIEDELQIPVK 2 y3, y4, y9
FELTC[+57]YSLAPQIK 2 y4, y5, y7, y8
NQAPPGLYTK 2 b3, y3, y6
GLVSLK 2 b4, y3, y4
ETFEDC[+57]NLLPK 2 y3, y6, y7, y9




EIEYEVVR 2 y3, y4, y5, y6
TLGVDLVALATR 2 b3, y7, y8, y10
LFVEALGQIGPAPPLK 3 y3, y4, y6, y7
YSTDVSVDEVK 2 y4, y6, y8, y9
VYEGSILEADC[+57]DILIPAASEK 3 y3, y6, y7, y8
IIAEGANGPTTPEADK 2 y5, y6, y8, y9
EYLPIGGLAEFC[+57]K 2 y3, y8, y9, y10




LFLLADEVYQDNVYSPDC[+57]R 3 b3, y4, y5, y6
ALELEQELR 2 y3, y4, y7
LLVAGEGR 2 y4, y5, y6
LTEQVFNEAPGIR 2 y4, y5, y7
DSPGETDAFGNSEGK 2 y6, y7, y8, y10







































Precision and accuracy of longitudinal label-free PRM 
The longitudinal effects (6, 12, 24, and 48 hours) of LPS, IFN-γ, and 
LPS/IFN-γ on the WCP and SEC in BV2 cells were analyzed using the final 217 and 
146 target proteins in PRM mode, which was performed on the same mass 
spectrometric system as in the discovery stage. One hundred seventeen raw files for 
the WCP and SEC groups were imported into Skyline for manual peak integration. 
A plot was generated and exported using the normalized XIC peak areas of the 
precursors and LRP. Fourteen of 15 iRT peptides were detected in the WCP group, 
versus 10 iRT for the SEC group. The average CV of the elution time for the detected 
iRT peptides between 234 runs was 0.43%. The average CVs of normalized XIC 
peak areas for the WCP and SEC groups between 117 runs were 20.85% and 24.27%, 
respectively (Table 2-2). 
 




The variability in repeat measurements of the same targeted peptides was 
defined as the technical CVs, whereas that across biological replicates was expressed 
as the biological CVs. Technical CVs were calculated as described in the methods 
section with each normalized XIC peak area of the targeted peptides, and biological 
CVs were determined with the mean CVs of normalized XIC peak areas in technical 
triplicates. The median CVs of target peptides in the WCP group were 6.07% and 
9.09% for technical and biological replicates, and those of the SEC group were 5.02% 
and 14.25%, respectively. As shown in Figure 2-9 A, the values were less than 20%, 
indicating good precision in the label-free PRM. 
To compare the quantitative differences due to the various labels, the 
correlation coefficients of redundant proteins in the same treatment and at the same 
time point (24 hr) between the discovery and targeted analyses were measured with 
the R-squared statistic, which was 0.7959 for the WCP and SEC experiments (Figure 
2-9 B). This result indicates that both approaches had high correlation and 
reproducibility. 
To compensate for the drawbacks of the label-free targeted analysis, a 
single high-purity heavy isotope-labeled reference peptide (LRP) and multiple 
heavy-labeled iRT peptides were used to normalize endogenous target peptides and 
retention times, allowing me to assess and improve the system by LRP normalization 
and correct for the variations in retention time shifts between LC runs by RT 
regression. I examined how normalization by LRP affected the results of the PRM 
analysis in the WCP and SEC groups by comparing the distribution of technical CVs 
of the iRT peptides before and after normalization (Figure 2-9 C, D). The CVs of 
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normalized endogenous target peptides by LRP demonstrated better performance 
than before the normalization, as shown in Figure 2-10. 
 
Figure 2-9. Characterization of label-free PRM analysis 
(A) CVs between technical replicates and biological replicates in the WCP and SEC 
groups were plotted to determine the precision of the label-free PRM analysis. Box 
and whisker plots with statistical summaries were calculated in MedCalc (Ver. 
12.3.0.0). (B) Redundant proteins between the discovery and targeted analyses were 
compared using the ratio of the treated versus control group at 24 hours. (C, D) CVs 
before and after normalization using LRP were compared in iRT heavy-labeled 
peptides. The CVs of the technical triplicates were calculated using Excel and drawn 




Figure 2-10. Distribution of XIC peak areas before and after normalization. 
CVs before and after normalization using LRP were compared in all targeted 
peptides for the (A) WCP and (B) SEC groups. The CVs of technical triplicates were 





Intracellular protein expression alteration by microglia activation 
The normalized XIC of peak areas of target peptides were analyzed 
statistically in MSstats, based on linear mixed models. By longitudinal PRM analysis 
of target proteins, I observed several inconsistently expressed proteins between the 
3 treatment groups. Of 217 target proteins in the WCP group, 176 were significantly 
changed, based on an adjusted p-value < 0.05, whereas 41 were unchanged between 
groups during activation (Figure 2-12A). In the Toll-like receptor pathway, 25 
proteins were upregulated over time in each treatment group, whereas 6 were 
downregulated (Figure 2-11 A). With regard to the NK cell-mediated cytotoxicity 
pathway, 29 proteins rose and 5 proteins decreased over time under each condition 
(Figure 2-11 B). For antigen processing and presentation, LPS, IFN-γ, and their 
combination induced MHC I (Figure 2-11 C). These findings are consistent with 
studies that have concluded that microglia express MHC I and present antigens to T 
and B lymphocytes when stimulated 56-57.  
Most proteins that are associated with metabolism were downregulated on 
stimulation. Several enzymes that mediate glutamate metabolism, such as Gfpt1, 
Gfpt2, Cad, and Cps1, were exceptions that increased after treatment with LPS or 
IFN-γ (Figure 2-11 D, E). This result confirms earlier conclusions that microglia 
release substantial levels of glutamate once they are activated by pro-inflammatory 





Figure 2-11. Proteomic changes in the WCP group 
Five distinct pathways related to microglial activation were selected from the KEGG 
pathway enrichment list: (A) Toll-like receptor signaling, (B) natural killer cell-
mediated cytotoxicity, (C) antigen processing and presentation, (D) glycolysis and 
gluconeogenesis, and (E) alanine, aspartate, and glutamate metabolism. Heatmap of 
fold-change in expression compared with control group was visualized using Perseus. 




Figure 2-12. Significant proteomic changes and PPI network proteins in the 
WCP group 
Significant proteomic changes in each treatment group against the control in the (A) 
WCP and (B) SEC groups were analyzed using MSstats, based on the linear mixed 
model package in R. NS indicates a non-significant change, with an adjusted p-value 
less than 0.05. (C) Temporal changes in the proteome that interact or bind with 
proteins associated with a KEGG pathway. 
 
76 
Quantitative network map of dynamic proteome during microglial activation 
Despite the knowledge of what roles protein play in microglia activation, the 
alteration network of proteome during activated microglia remains unclear. PPI 
network model was constructed to track the proteomic changes in the 5 pathways 
during microglial stimulation (Figure 2-13). In inflammatory responses, Tnf, Cxc110, 
and Jun were upregulated during the early stages of LPS treatment. In contrast, Cd40, 
Pik3cb, Chuk, Ikbke, Plcg1, H2-Q10, and Ctsb rose during the later stages of LPS 
stimulation. Several proteins were downregulated, such as Ifi30, Bid, Grb1, Nfyb, 
and Nfyc.  
Of the proteins that were associated with metabolism, Gfpt2, Pfkp, Adh5, 
and Adssl1 increased gradually during activation, whereas Aldoa, Aldoc, Eno3, 
Ldhc, Pgam1, Got1, Got2, and Gpt fell over time (Figure 2-13 A). Unlike the LPS 
group, IFN-γ treated microglial cells produced Ifng, Fcgr4, and Cxcl9 early during 
stimulation, and Spp1 and Cd14 declined compared with the control group during 
the later stages of activation. Hk3 and Pklr levels rose toward the end of the 
stimulation, whereas Aldh7a1 increased early on (Figure 2-13 B). Although the 
levels of proteins in the LPS/IFN-γ treated group generally remained unchanged 
versus the individual treatments, Grb, Cd14, and H2-Q1 content was more similar to 
that in the LPS treated group, and Spp1, Pfkp, Cxc19, Icam1, Ifng, and Tab1 
approximated such levels in IFN-γ treated cells (Figure 2-13 C). The results of the 
PPI network model support that stimulation of microglia activates immune and 








Figure 2-13. Proteomic changes in pathway networks. 
Significantly changed proteins between control and (A) LPS, (B) IFN-γ, and (C) LPS 
plus IFN-γ treatment were visualized in Cytoscape (ver 3.4.0) with the PPI network 
from STRING. Enriched proteins in the 5 pathways were clustered into gray boxes. 
Blue and red represent down- and upregulation, respectively, of proteins with log2 
fold-change obtained from the PRM analysis; the size of the nodes was mapped with 
the absolute fold-change value. The depth of the edges indicates the PPI score using 




Secreted protein expression alteration in activated microglia 
I determined which proteins were secreted by activated microglia versus 
astrocytes, neurons, and other cells in the surrounding environment. Total 141 
secreted proteins changed their expression level during microglial activation, based 
on an adjusted p-value < 0.05 (Figure 2-12 B). By GO analysis of the target proteins, 
3 terms were enriched: immune response, lysosomal acid hydrolase activity, and 
cytokine activity (Figure 2-7 B). Of the 141 proteins, 29 were related to the immune 
response (Figure 2-14 A). Whereas most of the secreted cytokines were released at 
high levels on LPS, IFN-γ, and LPS/IFN-γ stimulation, the secretion of 3 (C1qa, Cfh, 
and C1qc) was higher only with IFN-γ treatment. Notably, LPS alone had a stronger 
effect on Cxcl2, also known as macrophage inflammatory protein 2, a chemokine 
that is induced by IL-17. These results are consistent with earlier transcriptome data 
60-61.  
Further, 37 of the 141 target proteins are involved in lysosomal acid 
hydrolase activity (Figure 2-14 B), 5 of which (Cd38, Hmox1, Furin, Cndp2, and 
Ehd1) increased gradually over time; the secretion of 2 (Esd, Eif4a1) rose only at the 
outset of activation. Acp5 was upregulated only during LPS treatment and decreased 
when with IFN-γ. Twenty-three target proteins had molecular functions in cytokine 
activity (Figure 2-14 C). The secretion of Grn, Pf4, and Tnfsf13b declined over time 
with LPS and IFN-γ treatment, whereas Ccl2 and Tnfsf9 increased exclusively with 
LPS. Thus, our analysis of proteins that are secreted by endotoxin-activated BV2 
microglia demonstrates that the secretion of inflammatory cytokines is enhanced, 













Figure 2-14. Proteomic changes in the SEC group  
Three representative molecular functions of DESPs (A) immune response, (B) lysosomal acid hydrolase activity, and (C) cytokine activity were 
revealed by GO analysis on the DAVID website. (D) Ten redundant proteins in the WCP and SEC groups were compared with regard to expression 




Differential proteins between intracellular and extracellular 
 Of the target list in the PRM analysis, 10 proteins were simultaneously 
quantitated in the WCP and SEC groups (Figure 2-14 D). Six (Cxcl9, Cxcl10, Icam1, 
Ifng, Lgmn, and Ncf1) of the proteins were altered with same pattern at intra- and 
extracellular locations, but expression level of Tnf was higher at the WCP group than 
SEC group in IFN-γ treated microglia. Moreover, Sqstm1, a late endosome protein 
and an extracellular exosome marker, underwent few changes in secretion compared 
with the WCP group, rising gradually in secretion during microglial activation.  
Notably, Gpi and Spp1 developed contradictory expression patterns in the 
2 groups they were downregulated overall in cells but their secretion increased. Gpi 
is a cytosolic glycolytic enzyme, and in mammals, it functions as a neurotrophic 
factor for spinal and sensory neurons when secreted 62. While function of Spp1 in 
extracellular space were well known as neurotrophic factor or cytokine of immune-
inflammatory responding 63, the expression and function of Spp1 in immune cells 
are not sufficiently defined. Recently, intracellular Spp1 was found to inhibit TLR 
signaling and effect on liver carcinogenesis 64. These results indicate that the 
intracellular and extracellular functions of these proteins differ and that the activation 
of microglia effects neurotrophic activity. 
 
Microglia specific expression proteins 
 I conducted a meta-analysis with transcriptome data to further identify 
markers for proteins that specifically expressed in microglia. I compared the target 
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proteins used in PRM analysis with 1016 genes known to express microglia 
specifically by RNA-sequencing 65 (Figure 2-15 A). Among the transcriptome data, 
proteins overlapping with proteomics data were 42%, of which 53 proteins were 
DEPs at discovery level (Figure 2-15 B). The proteins are specific for expression in 
microglia, different from those expressed in astrocyte, neuron, and oligodendrite cell 
lines. As a result, I were able to get a list of the proteins for WCP group and SEC 
group in Table 2-3 and 2-4, respectively. Using the linear mixed model in the Msstats 
analysis, I selected only those proteins with a statistically significant (adjusted p-
value <0.05). Among these proteins, only those molecules known as microglia 
specific proteins based on a transcriptome database were selected and sorted. When 
microglia activation was performed by treatment with small molecules, it was found 
that most of the changes in the amount of protein in the cells lysate occurred after 24 
hours, while the secreted proteins were responded quickly within 6 hours after the 
treatments. I have presented 34, 41, and 41 proteins within the cell as microglia 
specific activation markers that vary dynamically in the LPS, IFN-r, and LPS + IFN-
r combined treatment groups. In addition, 47, 37, and 49 extracellular secreted 
proteins were presented as activated microglia specific secretome markers. Proteins 
on this list could be used as an important marker of intracellular and extracellular of 
activated microglia in the further study, and are expected to be very useful as a major 
marker of neurodegenerative disease including amyotrophic lateral sclerosis, 




Figure 2-15. Comparison proteomics data with transcriptome data to reveal 
microglia specific proteins. 
(A) The Venn diagram shows the degree of crossing between the transcriptome data 
of mRNA known to be expressed in microglia and the WCP group protein of 
activated microglia found in this study (B) The pie chart shows the distribution of 
microglia specific mRNA and proteins found in this study. The sub-chart shows the 




Table 2-3. List of cell specific differentially expressed proteins on WCP group  
 
Continue…  
log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue
Cxcl10 3.46477 0 3.25224 4.82E-14 3.68389 0 3.63506 0
Tnf 5.46743 0 5.59178 0 5.34025 0 6.09681 0
H2-Q10 0.26859 0.662065 0.68506 0.017148 1.01429 2.61E-05 1.80346 1.28E-12
Ifi30 -0.5439 0.244524 -0.8199 0.022981 -1.3361 1.03E-05 -2.1797 3.45E-12
Tlr9 -0.1588 0.694165 -0.3868 0.040621 -0.3459 0.035522 -1.0213 1.06E-10
Fcgr4 1.22076 2.36E-09 1.29016 3.33E-10 1.10044 4.07E-08 1.15687 3.03E-09
Eno3 -0.5822 0.890512 -0.8426 0.679106 -1.8717 0.0932 -4.973 4.98E-07
Bid -0.4043 0.898889 -0.2583 0.939655 -1.2092 0.166258 -3.3886 5.75E-06
Tapbp 0.56922 0.064584 0.73801 0.00563 0.81164 0.000479 0.86233 7.00E-05
Tlr13 0.10989 0.953298 -0.2446 0.754354 -0.2283 0.604241 -1.1512 0.000515
Rela 0.265 0.887492 0.23385 0.83565 0.43138 0.395116 1.28952 0.000914
Itgax 0.15276 0.887492 0.06079 0.939655 0.01757 0.949969 0.74766 0.001335
Cyba 0.09775 0.991868 0.21069 0.939655 0.07801 0.934868 -1.9413 0.001554
Fcgr1 0.25414 0.804111 0.40343 0.466135 0.28799 0.433928 -0.8752 0.001607
Ncf4 0.17463 0.940081 0.25528 0.857937 0.80969 0.141433 1.40172 0.00199
Ptpn6 -0.0391 0.991868 0.06473 0.939655 0.16991 0.535928 0.59607 0.003007
Sord -0.509 0.636827 -0.3667 0.665249 -1.0808 0.016092 -1.1661 0.003152
Ncf2 0.29333 0.700864 0.25085 0.665249 0.38548 0.269202 0.78644 0.003482
Nfkb2 0.33259 0.794404 0.48487 0.505513 0.71699 0.082543 0.99125 0.004478
Inpp5d 0.08504 0.940081 0.23717 0.622407 0.23948 0.433928 0.62986 0.006316
Itgam 0.04745 0.991868 0.05628 0.939655 0.28934 0.358426 0.62947 0.008291
Itgb2 -0.012 0.999653 -0.1186 0.939655 0.37463 0.492659 1.03929 0.011488
Ctsb 0.00089 0.999653 -0.1159 0.939655 0.34712 0.426774 0.81239 0.013094
Relb 0.24151 0.92634 0.35911 0.754354 0.67242 0.279117 1.18846 0.013094
Pik3cg 0.30176 0.623991 0.36487 0.38388 0.50104 0.061604 0.54918 0.015132
Vav1 0.32284 0.887492 0.36813 0.7004 0.62383 0.279117 1.05214 0.018083
Nfkb1 0.07789 0.991868 0.46643 0.631304 0.34309 0.589716 1.08055 0.02078
Myd88 0.19015 0.831693 0.34141 0.438015 0.27237 0.355974 0.47033 0.035293
Tlr7 0.43696 0.127934 0.13898 0.754354 -0.0273 0.923587 -0.3889 0.037959
Cd14 0.88848 0.222043 1.06681 0.077904 0.89255 0.079631 0.88861 0.039152
Hk2 0.03354 0.991868 0.39429 0.180947 0.08243 0.774845 0.39105 0.044981
Ptk2b 0.04545 0.991868 -0.0575 0.946388 0.02621 0.949969 0.65883 0.047086
Spp1 -0.1047 0.940081 -0.0181 0.964297 0.52602 0.124529 0.55317 0.049928
Fcer1g 0.48426 0.096262 0.3514 0.252707 0.66961 0.001527 0.34426 0.06961
LPS treatment in WCP





log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue
Cxcl10 3.92696 0 4.52446 0 4.61119 0 4.24949 0
Fcgr4 2.65939 0 3.14734 0 2.6146 0 2.42782 0
Ifi30 -0.3476 0.632536 -0.4185 0.280505 -1.4965 3.48E-07 -2.8953 0
Spp1 -0.0198 0.989224 -0.3887 0.33797 -1.3474 5.22E-06 -2.5072 2.75E-14
Hk3 -0.0153 0.989224 0.21759 0.592033 1.00531 0.000124 1.84322 4.14E-11
Tapbp 0.56729 0.039186 1.28651 3.31E-08 1.43051 8.79E-10 1.46439 1.76E-10
Bid -0.6575 0.793819 -0.6152 0.592033 -2.7041 0.000251 -4.4826 5.05E-09
Tnf 2.42024 3.95E-08 3.10032 8.19E-12 2.22711 1.38E-07 2.36012 1.45E-08
Ptpn6 -0.0205 0.989224 0.15575 0.624565 0.63848 0.001603 1.13347 6.45E-08
Inpp5d 0.19691 0.818112 0.31752 0.33797 0.86598 0.000243 1.1752 7.11E-07
Tlr13 -0.0597 0.989224 -0.1836 0.733692 -0.8036 0.013847 -1.6114 1.35E-06
Ncf2 0.09478 0.989224 0.25713 0.550073 1.04192 0.00017 1.2886 2.56E-06
Cd48 -0.1395 0.944813 -0.0645 0.876227 -0.5489 0.015545 -1.0089 1.04E-05
H2-Q10 0.24296 0.725592 0.8295 0.000595 0.8591 0.000158 0.93875 2.26E-05
Icam1 1.21734 0.008613 2.06096 3.60E-07 1.8135 3.13E-06 1.56503 2.43E-05
Sord -0.5773 0.507119 -0.738 0.156345 -1.7966 1.30E-05 -1.5536 7.64E-05
Tlr7 0.28449 0.473821 0.21741 0.438145 -0.2951 0.118794 -0.704 0.000142
Cd14 -0.4666 0.725592 -0.3439 0.607353 -1.357 0.001722 -1.6145 0.000153
Irf5 0.15457 0.989224 0.39708 0.564206 1.3183 0.00272 1.57693 0.000266
Pik3cg 0.09811 0.989224 0.29878 0.368646 0.83801 0.00028 0.8135 0.000268
Nfkb2 0.08407 0.989224 0.40539 0.438145 1.08629 0.001968 1.18587 0.000536
Rela 0.19211 0.989224 0.44442 0.438145 0.98818 0.010286 1.27911 0.000726
Ncf1 0.65432 0.818112 1.13261 0.280505 2.28767 0.002304 2.43238 0.000912
Myd88 0.15938 0.894157 0.29808 0.361183 0.71411 0.001521 0.71967 0.000956
Itgam 0.10491 0.989224 0.04355 0.926359 -0.3747 0.122607 -0.725 0.001997
Ncf4 0.06683 0.989224 0.36636 0.60452 1.2245 0.006858 1.36481 0.002027
Vav1 0.32587 0.888602 0.36746 0.600963 1.26638 0.004579 1.33002 0.002308
Relb 0.02373 0.989224 0.50859 0.489583 1.29968 0.006884 1.37248 0.003445
Plcg2 -0.0522 0.989224 -0.048 0.946012 0.58286 0.115083 0.96203 0.006661
Eno3 -0.7622 0.831692 -0.945 0.522 -1.4925 0.118595 -2.4453 0.007749
Lcp2 0.10122 0.989224 0.71303 0.444032 1.29682 0.041147 1.43556 0.018677
Btk 0.30878 0.879696 0.3558 0.585269 0.96617 0.017446 0.91852 0.019108
Sirpa 0.09467 0.989224 -0.0208 0.978406 -0.7338 0.118486 -1.0362 0.020309
Hk2 -0.0487 0.989224 0.13845 0.653836 0.38611 0.04948 0.41939 0.02644
Itgax 0.219 0.777605 0.28728 0.404229 0.36004 0.124355 0.489 0.029119
Pik3cd -0.0185 0.989224 0.04937 0.965761 0.65764 0.264753 1.18754 0.030189
Nfkb1 0.10374 0.989224 0.3608 0.626608 0.80765 0.089303 0.95044 0.035824
Ptk2b -0.2477 0.882017 -0.5848 0.20218 0.11193 0.765729 0.66869 0.036513
Lgmn -0.8422 0.355987 -0.7974 0.255878 -1.126 0.021295 -0.9246 0.048416
Fcgr1 0.67562 0.070416 0.95261 0.001712 0.82773 0.002802 0.37269 0.161158
Itgal 0.11416 0.902981 0.58643 0.001129 0.12858 0.45727 -0.099 0.535409
Protein 24hr 48hr6hr 12hr




log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue
Cxcl10 5.57955 0 5.91902 0 6.66394 0 5.85293 0
Fcgr4 2.5726 0 2.71025 0 2.34087 0 2.30419 0
Ifi30 -0.6883 0.045998 -0.9238 0.002299 -1.6834 1.85E-08 -3.2453 0
Spp1 -0.4327 0.330491 -0.544 0.110024 -1.4096 1.95E-06 -2.8778 0
Tnf 5.13562 0 5.80484 0 5.34843 0 6.11683 0
Tapbp 0.93162 7.72E-05 1.34383 7.46E-09 1.54346 5.57E-11 1.68259 1.25E-12
H2-Q10 0.53465 0.055194 0.84642 0.000412 1.28754 6.23E-08 1.4908 3.67E-10
Bid -0.7641 0.560082 -0.9411 0.34696 -2.8957 0.000106 -4.8001 5.35E-10
Icam1 1.97903 1.35E-06 2.47576 1.78E-09 2.37173 4.27E-09 2.18192 1.93E-08
Tlr9 -0.1566 0.539045 -0.128 0.522859 -0.1917 0.199148 -0.8104 4.85E-08
Eno3 -1.0605 0.527519 -1.1849 0.365262 -2.5667 0.007149 -4.9495 3.69E-07
Hk3 0.05746 0.930551 0.30115 0.387977 0.52707 0.041016 1.19559 3.82E-06
Tlr13 -0.1469 0.826783 -0.5525 0.179542 -0.8455 0.010725 -1.419 1.67E-05
Sord -0.723 0.195996 -1.1117 0.011032 -1.7723 1.66E-05 -1.7015 1.81E-05
Ptpn6 0.0579 0.921681 0.10534 0.692468 0.55791 0.005994 0.83189 3.16E-05
Ncf2 0.2994 0.536917 0.15632 0.669123 0.95706 0.000541 1.07988 5.57E-05
Myd88 0.33109 0.341554 0.25378 0.409639 0.73448 0.001179 0.8902 5.57E-05
Rela 0.71222 0.192966 0.58304 0.235546 1.20759 0.002096 1.52753 6.59E-05
Tlr7 0.28372 0.334576 0.22726 0.376822 -0.351 0.066064 -0.7074 0.000124
Nfkb2 0.45774 0.422424 0.63613 0.136513 1.26113 0.000431 1.29238 0.000169
Cyba 0.12275 0.930551 0.43329 0.614843 -0.138 0.832446 -2.0927 0.000488
Inpp5d 0.10577 0.826783 0.17433 0.59093 0.58847 0.011653 0.77434 0.00061
Ncf4 0.20155 0.826783 0.46499 0.464412 1.12127 0.014439 1.47854 0.000842
Relb 0.58399 0.463569 0.59197 0.376822 1.47823 0.002442 1.51112 0.001334
Fcgr1 0.39612 0.375125 0.51263 0.129311 0.29266 0.320924 -0.8283 0.002209
Irf5 0.3389 0.694288 0.48635 0.428334 1.07944 0.01505 1.30355 0.002386
Hk2 0.30633 0.316458 0.38982 0.097985 0.66237 0.00089 0.5758 0.002511
Lgmn -1.312 0.024751 -0.9383 0.110024 -1.1041 0.024665 -1.3544 0.00434
Itgax 0.01702 0.96762 0.13685 0.669123 0.29633 0.222074 0.63557 0.004914
Cd48 -0.0652 0.921681 -0.0735 0.827482 -0.4157 0.073355 -0.6195 0.005068
Nfkb1 0.56141 0.475829 0.35972 0.589627 1.07147 0.023943 1.23451 0.006919
Lcp2 0.5719 0.645995 0.97383 0.228454 1.55721 0.014913 1.65649 0.006954
Vav1 0.4407 0.604459 0.54809 0.376822 1.18636 0.008807 1.13339 0.008951
Pik3cg 0.23998 0.560082 0.26797 0.387977 0.74143 0.001296 0.54971 0.012205
Itgam -0.1704 0.730797 -0.2184 0.521926 -0.476 0.050618 -0.5617 0.015289
B2m 0.10209 0.930551 0.55839 0.455999 0.28595 0.622719 -1.2271 0.016726
Ncf1 0.96363 0.422424 1.24749 0.188373 2.15824 0.004485 1.68011 0.019964
Ptk2b 0.06695 0.930551 -0.1336 0.776437 0.35716 0.316254 0.7041 0.027501
Btk 0.18516 0.826783 0.35134 0.542544 0.84154 0.041016 0.81138 0.038087
Fcer1g 0.31584 0.272217 0.51758 0.015109 0.15048 0.476757 -0.2733 0.146979
Itgal 0.37083 0.083755 0.71208 6.05E-05 0.29785 0.077094 -0.02 0.902953
LPS+IFN-Ƴ treatment in WCP
6hr 12hr 24hr 48hrProtein
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Table 2-4 List of cell specific differentially secreted proteins on SEC group 
Continue…  
log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue
Acp5 4.77849 0 4.86113 0 4.49361 0 4.91289 0
Adam15 1.0862 2.50E-06 1.73085 1.82E-11 2.22287 0 2.69162 0
Ang -0.53 0.134784 -0.2387 0.5012 2.09927 1.38E-07 4.30057 0
B4galt1 6.26834 1.62E-14 7.12559 0 6.14529 2.43E-14 5.51018 8.86E-13
C1qa 1.22407 2.10E-09 1.10927 2.69E-08 1.32017 3.63E-10 1.2882 4.62E-10
C1qc -1.938 0.000759 -2.6114 1.00E-05 -3.1812 1.89E-07 -3.5422 1.28E-08
Ccl12 1.84757 4.81E-06 2.13454 2.16E-07 1.96757 8.34E-07 2.21506 8.06E-08
Ccl2 5.59272 8.17E-12 5.07426 1.68E-10 4.03037 7.75E-08 3.24608 5.53E-06
Ccl7 -1.013 0.003322 -1.1597 0.00075 -1.7672 7.77E-07 -1.5873 7.10E-06
Ccl8 0.93046 0.037345 1.49663 0.00099 1.46795 0.001067 1.98654 1.87E-05
Cebpb -0.7506 0.076524 -0.5088 0.23926 -0.6367 0.128525 -1.9146 1.87E-05
Cfh -1.1216 0.0234 -1.8807 0.00024 -2.1169 3.08E-05 -2.0665 4.82E-05
Cfp -0.8923 0.173994 -1.1777 0.07535 -2.0292 0.002397 -2.7876 5.23E-05
Cndp2 1.90583 3.23E-05 2.16882 3.38E-06 1.78093 6.69E-05 1.80006 5.67E-05
Csf1 -1.097 0.001358 -1.5485 1.26E-05 -1.3929 5.36E-05 -1.3741 6.34E-05
Cst7 0.58509 0.065441 0.99666 0.00216 1.06668 0.000877 1.25352 0.000111
Ctsd 1.85834 0.042253 3.19035 0.00065 2.83778 0.00186 3.38352 0.000258
Cxcl10 -1.0867 0.017431 -1.2775 0.00502 -1.7967 9.39E-05 -1.5205 0.000823
Cxcl2 0.59454 0.03018 0.73266 0.00782 0.80846 0.003006 0.89938 0.001109
Furin -0.2349 0.497836 0.03063 0.93652 0.24177 0.494936 1.08407 0.003805
Galns -1.8502 0.000973 -2.019 0.00035 -1.9706 0.000353 -1.5092 0.006365
Gdf15 0.57827 0.07863 0.66139 0.04833 0.69966 0.034035 0.84545 0.012959
Grn -0.8077 0.019217 -0.9225 0.00733 -1.0021 0.003128 -0.8336 0.015915
Hexb -0.5327 0.0234 -0.3819 0.09733 -0.739 0.001645 -0.5546 0.019558
Hmox1 -0.0807 0.774844 0.18244 0.52274 -0.0044 0.992764 0.66506 0.02409
Hp 0.55028 0.019612 0.25362 0.28172 0.26784 0.243031 -0.5284 0.025472
Icam1 -1.104 0.00072 -0.9022 0.00477 -0.9408 0.00283 -0.6183 0.057102
Il27 0.87824 0.000453 0.88043 0.00042 0.92836 0.000161 0.46593 0.059286
Isg15 0.51343 0.43539 1.29126 0.06002 1.96641 0.004331 1.27229 0.072811
Lgmn 3.95719 0 3.11249 2.46E-12 1.92294 6.11E-07 0.60075 0.105106
Lyz1 -0.5926 0.325592 -1.0716 0.07563 -1.693 0.005378 -1.0191 0.105106
Mapkapk2 1.28903 0.000222 0.99884 0.00318 0.87127 0.008665 0.53418 0.121277
Metrnl -1.0737 0.042694 -1.2212 0.02212 -1.3619 0.009144 -0.637 0.256934
Mmp19 -1.8325 0.008679 -1.2157 0.07535 -1.098 0.105023 -0.7835 0.286325
Mrc1 3.34568 2.01E-12 3.70631 8.10E-14 2.36092 4.93E-08 0.42503 0.301653
Napsa -0.9184 0.018212 -1.0839 0.00513 -0.9959 0.008665 -0.3912 0.330805
Ncf1 -0.9973 0.067985 -0.8856 0.10114 -1.1192 0.038368 -0.5096 0.374317
Olfm4 1.00649 0.016722 0.79441 0.05471 0.9186 0.024723 0.38002 0.377433
Pf4 1.25786 0.080031 1.56396 0.03411 1.24445 0.083863 0.63058 0.405928
Plek -0.9463 0.00117 -0.7534 0.00828 -0.516 0.067419 0.19946 0.516418
Pnp -0.8598 0.019612 -0.6993 0.05475 -0.4671 0.193408 0.25262 0.520614
Prkcd 0.73873 0.00033 0.63023 0.00188 0.6774 0.000709 0.13231 0.531258
Spp1 -1.3507 1.26E-09 -1.1505 7.18E-08 -1.0428 5.33E-07 -0.0769 0.736103
Protein 6hr 12hr 24hr 48hr





log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue
Acp5 2.64511 7.17E-05 6.29223 1.30E-14 7.13251 0 6.87385 0
Adam15 0.83521 0.00024 1.17547 5.78E-07 1.69056 2.63E-11 2.18796 4.05E-15
Ang 3.04209 4.35E-09 3.95185 8.00E-13 3.99091 6.74E-13 4.45629 6.48E-15
B4galt1 0.44918 0.23485 2.35855 1.78E-08 3.06409 7.89E-12 3.7085 6.48E-15
C1qa 0.69401 0.01528 0.80563 0.00369 1.31667 3.69E-06 1.68798 1.75E-08
C1qc 0.70156 0.04145 0.73657 0.03002 1.44533 2.26E-05 2.00755 3.13E-08
Ccl12 0.37126 0.31279 1.00529 0.00597 1.46523 6.32E-05 2.12362 5.37E-08
Ccl2 4.54746 0 4.388 0 2.75819 4.48E-10 2.24557 6.39E-08
Ccl7 -0.8259 0.00073 -0.7625 0.0014 -1.1067 4.95E-06 -1.3557 6.39E-08
Ccl8 -0.8344 0.01731 -1.1451 0.0009 -1.8154 4.41E-07 -1.8161 3.21E-07
Cebpb 4.01795 0 3.96205 0 3.12591 1.77E-12 1.90239 5.11E-07
Cfh 1.01692 3.66E-07 0.84753 1.01E-05 0.99566 2.43E-07 0.94118 5.23E-07
Cfp -0.5563 0.21056 -0.2901 0.50438 -0.7684 0.06304 -2.1069 2.04E-06
Cndp2 -1.943 0.00652 -2.0302 0.00369 -2.8546 4.58E-05 -3.2758 3.83E-06
Csf1 -1.5271 0.00817 -1.8623 0.00107 -2.4798 1.44E-05 -2.6172 4.56E-06
Cst7 0.39541 0.14384 0.95155 0.00039 0.91081 0.00037 1.17852 7.25E-06
Ctsd -0.6273 0.07489 -0.6335 0.07033 -1.1254 0.00085 -1.5377 9.26E-06
Cxcl10 -1.8449 3.66E-07 -1.1362 0.00072 -1.6345 1.62E-06 -1.4316 1.30E-05
Cxcl2 -0.5881 0.21018 -0.9681 0.03409 -1.6505 0.00024 -1.72 0.00013
Furin 0.84128 7.17E-05 0.69951 0.00068 0.76568 0.00012 0.74275 0.00017
Galns -0.6856 0.01995 -0.7916 0.0059 -1.0827 0.00014 -0.9056 0.0012
Gdf15 -0.6497 0.23223 -1.0106 0.06299 -1.5156 0.00341 -1.6686 0.00133
Grn -1.363 0.01701 -1.2299 0.02689 -1.4261 0.00718 -1.6276 0.0024
Hexb 1.83364 0.05023 2.69483 0.00366 2.82376 0.00165 2.67828 0.00276
Hmox1 0.89542 0.04613 1.38449 0.00179 1.2114 0.0044 1.15611 0.00628
Hp -0.9388 8.04E-06 -0.8115 7.43E-05 -0.9539 2.33E-06 -0.4971 0.00797
Icam1 -0.4042 0.23576 -0.2677 0.43779 -0.5538 0.08489 -0.8602 0.00802
Il16 -0.7149 0.21018 -0.933 0.09559 -1.4539 0.0066 -1.3895 0.00871
Il1rn 1.24334 0.00139 1.6206 5.54E-05 1.3447 0.00032 0.88092 0.01524
Il27 1.08124 0.01212 1.08916 0.00927 1.02857 0.01045 0.80987 0.04239
Isg15 -0.1038 0.77245 -0.1307 0.69138 -0.1129 0.71076 -0.6519 0.0431
Lgals3bp 0.50465 0.03871 0.43888 0.06769 0.31719 0.15575 -0.45 0.0446
Lgmn -0.9155 0.25902 -1.0994 0.1872 -1.5679 0.04428 -1.5148 0.04878
Lyz1 -0.7565 0.02051 -0.7483 0.01895 -0.7646 0.01262 -0.5891 0.05103
Lyz2 -0.0175 0.98625 -0.3502 0.56996 -1.229 0.03826 -1.1211 0.05514
Napsa 0.44249 0.53761 0.7355 0.31444 1.51207 0.0247 0.8683 0.19779
Spp1 0.51344 0.03983 0.57835 0.01821 0.69333 0.00341 0.14976 0.50547
Protein 6hr 12hr 24hr 48hr




log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue log2FC adj.pvalue
Acp5 1.85522 2.09E-06 2.78728 8.01E-11 3.24348 6.54E-13 3.96231 0
Adam15 0.76994 0.00039 1.7267 9.83E-12 2.68535 0 3.30143 0
Ang 7.71479 0 8.65536 0 8.39975 0 7.97518 0
B4galt1 1.06784 5.11E-08 1.46389 7.86E-12 1.5968 3.60E-13 1.761 1.18E-14
C1qa 4.01098 0 3.2629 8.10E-15 3.28789 4.05E-15 3.09114 2.49E-14
C1qc 2.46521 2.61E-07 2.93635 2.98E-09 3.00176 1.39E-09 3.67857 3.14E-12
Ccl12 -0.9727 0.02209 -0.8719 0.03164 -1.204 0.00307 -3.0567 2.51E-10
Ccl2 0.5306 0.05077 1.00719 0.0002 1.39663 7.67E-07 1.9301 3.29E-10
Ccl7 5.50125 0 3.93457 0 3.04745 1.96E-12 2.44437 9.53E-10
Ccl8 -0.6327 0.00696 -1.1888 1.04E-06 -1.4561 9.50E-09 -1.5828 9.76E-10
Cebpb -1.2038 0.00039 -1.7362 7.87E-07 -2.0617 1.25E-08 -2.1586 3.64E-09
Cfh 6.03791 4.54E-13 5.32477 2.23E-11 4.90234 1.95E-10 4.20706 8.46E-09
Cfp 0.97837 0.00021 1.0587 4.18E-05 1.1563 8.13E-06 1.59276 9.46E-09
Cndp2 -1.9651 0.00046 -2.6923 2.73E-06 -3.4165 1.32E-08 -3.4279 1.05E-08
Csf1 0.71145 0.00039 1.00189 1.11E-06 1.01458 7.30E-07 1.21439 1.12E-08
Cst7 -1.1902 0.00045 -1.7132 1.01E-06 -2.244 1.75E-09 -2.0283 1.62E-08
Ctsd -0.9514 0.00572 -1.1775 0.00045 -1.6406 2.48E-06 -2.0033 3.18E-08
Cxcl10 5.42031 0 4.45134 0 3.1674 5.55E-12 2.20841 6.33E-08
Cxcl2 0.42362 0.19529 0.92432 0.00387 1.31573 6.36E-05 1.80583 2.09E-07
Furin -1.2114 0.00696 -1.8126 5.54E-05 -2.602 4.69E-08 -2.3214 5.36E-07
Galns -1.053 0.00029 -1.5538 2.44E-07 -1.653 4.13E-08 -1.3618 2.41E-06
Gdf15 4.61371 1.75E-06 4.63021 1.05E-06 4.3411 2.95E-06 4.34914 2.63E-06
Grn -1.3284 1.54E-09 -1.5771 7.88E-12 -1.5085 2.33E-11 -0.8695 7.33E-06
Hexb -2.2416 0.00118 -2.9402 2.43E-05 -3.1312 6.81E-06 -3.1043 7.33E-06
Hmox1 2.33847 5.01E-07 1.85004 2.44E-05 1.86635 1.78E-05 1.82608 2.34E-05
Hp -1.0611 0.04293 -1.8075 0.00051 -2.2408 2.19E-05 -2.2017 2.68E-05
Icam1 -1.9531 0.0004 -2.5028 6.80E-06 -2.1556 6.23E-05 -2.2464 3.16E-05
Il16 -1.166 0.03198 -1.6623 0.00175 -2.1666 6.23E-05 -2.0573 0.00013
Il1rn -0.1912 0.56848 0.11114 0.74776 0.72751 0.0299 1.31781 0.00018
Il27 -0.8755 0.07043 -1.6381 0.00067 -1.9692 5.33E-05 -1.7652 0.00022
Isg15 -0.7744 0.23692 -1.0226 0.10085 -1.7142 0.00656 -2.3202 0.00033
Lgals3bp -1.1511 0.00034 -1.2012 0.00013 -1.2897 3.85E-05 -1.0471 0.00055
Lgmn -0.4845 0.41085 -1.4888 0.01017 -2.4331 5.62E-05 -1.9812 0.00071
Lyz1 -1.0645 0.00586 -1.423 0.00018 -1.5338 5.33E-05 -1.2313 0.00078
Lyz2 2.2529 5.11E-08 1.92095 9.95E-07 1.31816 0.0003 1.17904 0.00101
Mapkapk2 -0.9973 0.00669 -1.1828 0.0009 -1.314 0.00022 -1.078 0.0019
Metrnl -0.486 0.33052 0.14076 0.76739 0.93284 0.04804 1.48236 0.00237
Mmp19 0.93809 0.00016 1.3007 3.52E-07 1.12181 4.64E-06 0.6899 0.00256
Mrc1 0.86434 0.03446 0.83342 0.03261 0.91907 0.01728 1.11566 0.00426
Napsa -1.3369 0.08979 -2.1438 0.00514 -2.2786 0.00279 -1.9437 0.00989
Ncf1 0.01263 0.96569 -0.195 0.53548 -0.4285 0.163 -0.7704 0.01517
Olfm4 0.3847 0.09361 0.69063 0.00222 0.3796 0.07511 -0.5017 0.02067
Osm 1.17637 0.14946 1.65457 0.0363 1.86849 0.01728 1.76291 0.02364
Pf4 -1.0268 0.19936 -1.5505 0.04424 -1.6567 0.02959 -1.483 0.04994
Plek 0.53037 0.41983 1.56413 0.01724 2.11443 0.00142 1.17168 0.0654
Pnp -0.8343 0.2526 -0.9187 0.18724 -1.4752 0.03225 -1.0878 0.10995
Prkcd -0.4931 0.3471 -1.1002 0.03261 -1.035 0.03867 -0.7696 0.1203
Rnase4 0.66088 0.03509 0.2662 0.36656 -0.2198 0.43939 -0.2844 0.32452
Tnf 1.31833 0.00014 1.07909 0.00091 0.81799 0.00928 0.0939 0.75572
Protein 6hr 12hr 24hr 48hr




One of the goals of this study was to develop a systematic proteomic analysis 
method that eliminates the inconveniences that are caused by using 2 platforms for 
the global and targeted analyses. This aim was achieved using a dimethyl stable-
isotope labeling strategy and label-free PRM, based on orbitrap mass spectrometry, 
during the activation of microglia as our model. By obviating the need to preselect 
ions in the assay development stage, the conversion of DDA results to PRM data was 
accelerated. Moreover, with label-free PRM, over 450 peptides can be analyzed 
precisely in a single run. 
Another goal was to analyze the intracellular proteomic changes in immuno-
inflammatory responses and metabolic pathways and examine the intercellular 
proteins that accompany activation by endotoxin and pro-inflammatory molecules in 
a microglia cell line. In the pathway network model that resulted from the systematic 
analysis of the intracellular proteome, immuno-inflammatory responses tended to 
activate, whereas metabolic pathways were suppressed during microglial activation 
by endotoxin and pro-inflammatory molecules. These results are consistent with 
previous studies that have suggested a link between pro-inflammatory cytokine 
generation and mitochondrial function 66. Activation of local microglia induces them 
to function as antigen-presenting cells 67 and initiates TLR signaling, resulting in 
immune responses against microbial infections 68-70. Moreover, LPS inhibits 
metabolism in microglia through excessive synthesis of NO, which is harmful to 
adjacent neurons and the microglial cells that produce it 71-72. Our results support 
earlier findings on the function of metabolic reprogramming in the regulation of 
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innate inflammatory responses to LPS activated microglia. They also suggest that 
activating microglia with IFN-γ affects such metabolic pathways. Moreover, I 
quantified an additional 73 proteins that were not involved in any of the 5 pathways 
above but were associated with the pathways that were predicted by PPI (Figure 2-
12 C). For instance, Nox1, which mediates the release of ROS to eliminate invading 
microorganisms in macrophages and neutrophils, has been suggested to interact 
directly with Rac2 and transfer electrons from the cytosol to the membrane via a 
multidomain complex 73. The extra information of quantitative proteome for 
activated microglia could be useful for further study of the relationships between 
associated proteins. 
In addition to intracellular proteome, the secretome data shows that the 
microglial inflammatory response contributes to neuronal degeneration through 
excessive production of NO and other pro-inflammatory cytokines. For example, the 
secretion of macrophage migration inhibitory factor (Mif) decreased gradually after 
the initial exposure to bacterial toxins and cytokines. Mif mediates the innate 
immune response to endotoxin and gram-negative bacteria by modulating the 
expression of Toll-like receptor 4 (TLR4), a signal-transducing component of the 
LPS receptor complex 74. The expression levels of platelet factor 4 (Pf4) and 
granulins (Grns) also declined in the 3 treatment groups. Pf4, known as chemokine 
C-X-C motif ligand 4 (Cxcl4), is expressed specifically in microglia and is a ligand 
of Cxcr3, which is associated with various neurodegenerative diseases 75. According 
to Eiko et al., Cxcl4 attenuates LPS induced microglial activation, as evidenced by 
the reduction in NO production and phagocytosis 76.  
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Grn is a secreted form of progranulin (PGRN), which is cleaved by 
neutrophil elastase or proteinase. Despite our knowledge of the functions of Grn 77, 
the regulation of Grn in microglia has not been studied extensively. According to 
Suh et al, LPS suppresses PGRN secretion in human microglia, consistent with our 
data 78. Stimulation with LPS alone had a stronger effect on Tnf release than IFN-γ 
alone, supporting findings from the previous study 79, which showed that LPS 
induced Tnf production is independent of IFN-γ, whereas the induction of other pro-
inflammatory mediators, such as iNOS, is highly dependent on IFN-γ. Thus, the 
conversion of cytotoxic, classically activated microglia into anti-inflammatory cells 
over time can potentially prevent serious damage 80.  
Our systematic proteomic analysis has demonstrated that activation of BV2 
microglia with LPS or IFN-γ promotes pro-inflammatory activities, such as 
increased expression of MHC and lower secretion of lysosomal proteins. Additional 
studies will be needed to fully characterize the dynamics of protein expression 
patterns that are associated with the development of the pro-inflammatory and anti-





In this study, I examined the secretory proteins at the protein molecular 
level of the neuro-immune system in three cell lines including neuron and glia using 
high-resolution orbitrap based mass spectrometry. Not only did I look at the 
differences in the expression of the secreted proteins by each cell line through this 
dataset, but I could also see what pathways the proteins that differ in expression 
affect. I have also developed proteomics techniques for secretome analysis and have 
been able to utilize it in researching the proteomics of activated microglia. 
Moreover, our systematic quantitative approach using a high-resolution 
orbitrap allows me to evaluate the dynamic alternation of the whole-cell proteome 
and secretome during BV2 microglial activation. In particular, it was found that 
several proteins related to the immune-inflammation response and metabolism 
dynamically changed as cells responded to inflammation-associated molecules. 
These data will be integral in discovering biomarkers for neurodegenerative diseases 
that are associated with microglial activation. The development of a single platform 
that combines dimethyl-labeled shotgun proteomics and label-free PRM provides an 
alternative method of assessing peptides of interest that are unique to a specific 
protein in a large-scale targeted analysis. This platform will be beneficial for and 
applicable to a wide variety of fields in biology and neurodegenerative diseases from 
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고분해능 단백체 프로파일링 및  
표적단백체 기술을 이용한  
신경-면역 시스템에 대한 기능 단백체 연구 
 
 
서론: 의학의 발전으로 이제는 100 세 시대라고 할 정도로 인간의 
평균수명은 점차 증가하고 있지만, 노후화로 인해 발생하는 많은 질병 
중 Alzheimer disease (AD), Parkinson disease (PD), 또는 Amyotrophic lateral 
sclerosis (ALS)와 같은 퇴행성 뇌신경 질환은 삶의 질을 감소시키고 있다. 
이러한 퇴행성 뇌신경 질환의 원인과 기작에 대한 연구를 진행하기 위해 
분자수준에서의 접근이 필수적이며, 고해상도 질량분석기를 이용한 
프로테오믹스 기술은 이러한 표지자 단백질 발굴에 매우 유용한 기술로 
대두 되고 있다. 또한 표적 단백질 간의 체계적인 네트워크 분석은 향후 





방법: 1 장에서 중추신경계 세포들의 분비단백질 분석 최적화와 
세포주들간의 단백체 차이를 보기 위해 뇌신경세포주 (HT-22), 
성상교세포주 (C8-D1A), 미세아교세포주 (BV-2)를 사용하였다. 
1x10e6 개의 cell 을 100mm dish 에 24 시간 배양 후, 농축 시켜 얻은 
단백질들을 FASP (Filter Aided Sample Preparation) 기법을 사용하여 
펩타이드로 시료처리를 하여 고해상도 질량분석기기인 Q-Exactive 로 
4 시간 분석을 진행하였다. 분석결과 data 는 Andromeda 알고리즘 기반의 
MaxQuant 프로그램으로 데이터 처리를 하였고 annotation 되지 않은 
MS/MS 데이터는 de-novo 기반의 PEAKS-7 프로그램으로 분석하여 
추가적인 단백질 동정을 하였다. 각 세포주들의 분비단백질들은 label-
free quantitation기법으로 비교분석 하였으며 bioinformatics tool을 사용하여 
분비단백질들의 중요한 기능을 확인하였다. 2 장에서는 미세아교세포주에 
24 시간동안 lipopolysaccharide (LPS)와 interferon gamma (IFN-γ)를 처리하여 
활성화 시킨 후 intracellular 와 extracellular 에서의 단백체 차이를 dimethyl 
labeling 기법을 사용하여 동시정량분석을 진행하였다. 6, 12, 24, 48 시간동안 
LPS, IFN-γ, LPS/IFN-γ 로 활성화 시킨 미세아교세포의 intra-, 
extracellular 에서의 표지자 후보 단백질군에 대해서 변화를 보기 위해 
표적 단백체학 기법인 label-free PRM (Parallel Reaction Monitoring) 으로 





결과: 1 장에서는 고해상도 질량분석기를 사용하여 3 가지 세포주에서 
2795 개의 분비 단백질들을 동정하였으며 각 세포주 당 156 개 (BV-2), 
44 개 (C8-D1A), 93 개 (HT-22)의 특이적인 단백질을 발굴하였다. 또한 de-
novo sequencing 분석 기법을 사용하여 302 개의 추가적인 단백질들을 ID 
하였다. 발굴한 분비단백질들의 신뢰도를 높이기 위하여 SignalP, 
SecretomeP, Exocarta, TMHMM database tool 을 이용하여 2351 개의 잠재적 
분비단백질들을 분류하였고, 정량비교분석 기법을 통해 각 세포주 
분비단백질들간에 2 fold change 의 차이를 보이며 student t-test 에서 p-value 
0.05 이하의 유의수준을 보이는 단백질 573 개 (BV-2 vs. C8-D1A), 694 개 
(BV-2 vs. HT-22), 475 개 (C8-D1A vs. HT-22) 를 확인하였다. 또한 정량된 
단백질들의 pathway 분석을 통해 lysosome, phagocytosis 등과 같은 분비 
단백질들의 중요한 기능을 확인하였고, Parkinson disease, Huntington 
disease 와 같은 퇴행성 뇌신경 질환과도 연관이 있는 단백질들을 
발굴하였다. 2 장에서는 LPS 와 LPS/ IFN-γ 로 활성화 시킨 모델의 세포내 
단백체 (WCP) 분석을 통해 5492 개 단백질을 동정하였고 4748 개의 
단백질을 정량 할 수 있었으며 동일 모델의 세포외 분비단백체 (SEC) 
분석을 통해 4938 개 단백질 동정 및 3558 개 단백질을 정량 할 수 
있었다. 디스커버리 수준의 분석을 통해 유의한 차이를 보이는 단백질들 
과 KEGG pathway 등 bioinformatics 분석을 통해 319 개의 세포내단백질, 
170 개의 분비단백질을 최종 타겟 후보군으로 선정하였다. 450 개 이상의 
peptide 를 동시정량분석이 가능하도록 최적화 시킨 label-free PRM 기법을 
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사용하여 미세아교세포 활성화 시간대별로 모은 시료에서 표적단백체학 
분석을 진행한 결과, 시간대 별로 변화하는 pathway 네트워크 지도를 
그릴 수 있었으며 활성화 미세아교세포 모델에서 세포내와 세포외에서 
차이를 보이는 표지자 단백질 후보군을 제시 할 수 있었다.  
 
결론: 1 장에서는 분비단백체 기법의 최적화 및 개발을 통해 3 가지 
세포주들의 분비단백질 차이를 label-free quantification 기법으로 
확인하였다. 이러한 분비단백체학 기법은 적은 양으로 존재하고 있는 
세포외 단백질들을 심도 있고 정확하게 연구를 할 수 있는 기반을 
마련하였다. 2 장에서는 단일플랫폼에서 체계적인 정량 프로테오믹스 
접근법을 통해 중추신경계 안에서 면역을 담당하고 있는 미세아교세포의 
활성화 시 발현하는 표지자 단백질을 발굴하여 퇴행성 뇌신경 질환 
메커니즘 연구에 도움을 주고자 하였다. 보다 정밀하고 정확한 정량 
분석을 위하여 dimethyl labeling 동시 정량 기법과 label-free PRM 
표적단백체학 기법을 확립하였고, 미세아교세포의 활성화 시에 면역-
염증 반응과 신진대사에 관련한 단백질들의 변화를 하나의 플랫폼으로 
정량 분석하여 LPS 와 IFN-γ 특이적으로 발현의 차이를 보이는 표지자 
단백질들을 발굴 할 수 있었다.  
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주요어 : 중추신경계, 성상교세포, 미세아교세포, 뇌신경세포, 
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